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 Abstrakt 
Cílem této práce je vypracovat strategii vstupu produktu "A" farmaceutické společnosti "F" na český a 
slovenský trh. V této práci je tato strategie analyzována a hodnocena pomocí metody NPV (Net 
Present Value) a dalších metod. Na základě tohoto hodnocení je strategie vybrána. 
První kapitola zahrnuje teoretická východiska jednotlivých metod použitých pro účely této práce. Je 
zde zejména osvětlena metoda NPV a metody vhodné pro analýzu relevantních trhů, společnosti "F" 
produktu "A". 
Ve druhé kapitole je provedena analýza trhu České a Slovenské republiky a také analýza společnosti 
"F" a produktu "A". Tyto analýzy zahrnují jak vnitřní tak vnější potenciál společnosti i produktu. 
V závěrečné kapitole je vypracována navrhovaná strategie vstupu pro produkt 'A', jež je poté 
ekonomicky hodnoceny pomocí modelu NPV a dalších modelů. 
Abstract 
The purpose of this dissertation is to elaborate a specific market entry strategy of a product "A" 
manufactured by company "F". This market entry strategy is then analysed and evaluated by NPV 
(Net Present Value) method and others. Based on this evaluation the strategy is then selected. 
The first chapter covers theoretical and methodological background of methods used for the purpose 
of this paper. Mostly the NPV method is introduced followed by methods suitable for relevant 
markets, company "F" and its product "A" analysis.  
In the second chapter the Czech and Slovak market analyses are elaborated accompanied by the 
analysis of company "F" and its product "A". These cover both the internal and external potential of 
the company and its product.  
The last chapter analyses the elaborated market entry strategy of a product "A" accompanied by the 
economic evaluation using the NPV method and other methods. 
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2. Introduction 
Entering a new foreign market or markets represents a very important decision that 
company must make if it wants to sustain even more rapid growth. It is very important to 
consider carefully all aspects of this big step. Each of the markets has its own specific 
characteristics and trends that in many cases differ a lot from each other. In order to choose 
the right market in the fitting time it is needed to analyse these markets and then design a 
proper strategy to enter market successfully.  
The environment of the company is changing rapidly and it is then crucial not to stand 
behind. It is needed to continuously analyse the environment and seek for new 
opportunities that are created because of the changes. This enables the company to keep up 
with the competitors and thus sustain stable position in the market or even enlarge its 
market share and its value alone. These opportunities lie also in the possibility of launching a 
product on a market, which is the case of company ‘F’. 
The company ‘F’ is a well known company operating in the field of pharmaceutical industry 
all over the world. It is present also in the market of the Czech Republic and Slovakia.  The 
launching of the product brings up a vast number of questions that company ‘F’ has to 
answer before it can realise the launch itself. To these questions author concludes one of the 
most significant and recapping ones which are: ‘How to launch this product effectively and is 
it worth it to do that?’.  
The main goal of this thesis is to answer these pivotal questions with the support of a precise 
analysis, relevant arguments and suggestion of a suitable strategy. 
The first part includes the company introduction followed by the determination of the 
studied problem. It introduces the reader to the specifics of the market entering comprising 
both of its basic drawbacks and advantages. 
The second chapter brings the analysis of theoretical background supporting the analysis of 
the situation itself and also the proposal of appropriate strategy. It also outlines the 
methodology used. 
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The third part analyses the markets of the Czech Republic and Slovakia, the position of 
company ‘F’ on the market and the specifics of the product ‘A’. It applies the theories 
introduced in the previous chapter. The company marketing strategy is analysed by using the 
7 P’s Marketing Mix model. Also the main competitors are dissected. 
The last chapter evaluates the current company strategy. It then proposes the specific 
strategy for launching the product ‘A’. Finally the prognosis of sales is elaborated followed 
by the economic evaluation in a form of Net Present Value model and other relevant 
indicators. 
13 
 
3. Company introduction and problem determination 
a. Company introduction 
The history of the company ‘F’ is relatively rich touching the early twentieth century. It was 
established in 1931 in USA (Company ‘A’,  2011a). Its headquarters is situated in Deerfield in 
Illinois (USA). Originally it pioneered the intravenous therapy solutions. In 1954 it expanded 
to Europe by founding an office in Belgium. During the 1980’s and 1990’s it grew fast thanks 
to the help of numerous acquisitions and mergers. These actions contributed also to 
enlargement of its portfolio by offering vaccines and a variety of blood products (Company 
‘A’, 2011b).  
Today its primary target represents drugs treating haemophilia, kidney diseases, immune 
disorders, infectious diseases trauma, and other chronic and acute medical conditions. It is 
mainly a developer of new original branded drugs which puts a strong emphasis on the 
Research and Development (R&D) spending. In 2010 it spent 915 million USD on R&D. 
Thanks to that company ‘F’ uses the most modern and innovative technologies for 
development of drugs of a highest quality and efficacy which makes it one of the leading 
companies in this area. Company ‘F’ employed 47 600 people and reached sales of 12.8 
billion USD in 2010. Most of its sales come from USA representing 41 % of total sales. The 
second position takes Europe with 33 %, third Asia and Pacific with 14 % and last Latin 
America and Canada with 12 %. In Europe it is present in Austria, Belgium, Czech Republic, 
Germany, Ireland, Italy, Malta, Poland, Spain, Switzerland and the United Kingdom. 
Company ‘F’ is divided into three main manufacturing divisions including Bioscience, 
Medication delivery and Renal division. The bioscience the recombinant and plasma-based 
proteins to treat haemophilia and other bleeding disorders, plasma-based therapies to treat 
immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and 
acute blood-related conditions, products for regenerative medicine, such as bio-surgery 
products and vaccines can be concluded. This area is the largest and represented total sales 
of 5.7 billion USD in 2010 (Company ‘A’, 2011c). Company ‘F’ is also a leader in production of 
these products. 
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The second largest division is Medication delivery. The sales reached 4.8 billion USD in 2010. 
To this group belong the intravenous (IV) solutions and administration sets, premixed drugs 
and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV 
nutrition products,  infusion pumps, as well as products and services related to pharmacy 
compounding, drug formulation and packaging technologies. The most relevant products for 
this dissertation are inhalation anaesthetics that belong to this division. Company ‘F’ is one 
of the most successful manufacturers in all these areas. 
The smallest portion of sales worth 2.4 billion USD is generated via renal division. Company 
‘F’ manufactures products to treat end-stage renal disease, or irreversible kidney failure and 
other products used in dialysis therapy.  
b. Problem determination 
This part analyses the basic specifics and problem areas of the successful launch of product 
‘A’. It only determines these problems. The deep analysis and solution proposal are 
delivered in subsequent sections. 
The intention of company ‘F’ is to launch product ‘A’ on Czech and Slovak market. This drug 
is an anaesthetic agent. To understand the background it is important to outline the 
development of this drug. Company ‘F’ launches this product as a generic drug. The fact is 
that it originally invented this product. Then it licensed it to one Japanese pharmaceutical 
company. It then licensed this drug to another company, which then brought it on the 
market as an original drug1. This drug is very successful and thus company ‘F’ wants to grab 
sales also for itself. That is why it has already launched the generic drug on US market and 
also on other markets. 
However, there are a few significant problems regarding the successful launch. These most 
important problems can be identified as: 
- Low and even diminishing market share of company ‘F’ on inhalation anaesthetics 
market 
                                                      
1
15 
 
- High entry barriers 
- Strong competition 
- Defocused area of company ‘F’ of inhalation anaesthetics market 
- Price war with another anaesthetic agent (Isoflurane) 
- No extensive usage of another anaesthetic agent (Desflurane) 
- Determination of costs and return on investment 
Company ‘F’ is present on the market of inhalation anaesthetics even now in the Czech 
Republic and Slovakia, but plays only a marginal role and also its market share is shrinking. 
This is caused by more factors. There is a very strong competitor ‘B’ that is ruling most of the 
market and is even increasing its share.  
There is also a high barrier to enter this market represented by the necessity of providing a 
special machine called vaporizer that is used for preparation of the right concentration of 
specific inhalation anaesthetic agent. The competitor has already placed much of them in 
the customers’ facilities. This also brings high initial costs to provide the vaporizers as they 
are relatively expensive. 
Another reason for the low and diminishing market share is the presence of price war on 
Isoflurane, which decreases the value of sales. Isoflurane is also being driven out by more 
modern and more effective anaesthetic product ‘A’ of the main competitor ‘B’, which is also 
supported by a strong marketing campaign of company ‘B’.  
Negative factors are represented also by diminishing usage of other inhalation anaesthetic 
desflurane of company ‘F’, which is being replaced by other anaesthetics.  
Finally it is crucial to estimate the costs properly, calculate the return on investment and 
thus determine whether it is worth it to put such an effort to succeed in this area or not. 
These are the main problem areas that have to be overcome in order to successfully launch 
the product ‘A’ and thus improve the position of company ‘F’ on the inhalation anaesthetic 
market.   
16 
 
4. Theoretical and methodological background 
a. Theoretical background 
This part is dedicated to the analysis of theoretical tools that are used to analyse and 
evaluate the current position of company ‘F’ and to elaborate the launching strategy for 
product ‘A’. These include the tools for analysis of both the market and the company such as 
PESTEL analysis, Porter’s five forces analysis, SWOT analysis, Risk analysis, Segmentation, 
EPRG model of internationalisation and 7 P’s Marketing Mix model.  
i. PEST analysis 
This very famous and popular analytical tool is used to analyse the external (macro) 
environment the company faces. It takes into consideration all the external factors that are 
influencing the position of the company. These factors cannot be influenced by the 
company. It is divided into six separated areas: political/legal, economic, social/cultural and 
technological (Machková, 2006).  
Political and legal factors 
This area is focused on the environment that is formed by state authorities. It studies mainly 
the stability of political system. It also traces the valid laws influencing the general business 
activity and also the specific branch of industry. These include laws such as antitrust laws, 
consumer protection laws, employment laws and other specific laws. It is also important to 
point out the international trade regulations and restrictions, environmental regulations and 
protection, safety regulations, tax and customs policy, attitude of governmental 
organisations, lobby, corruption, law enforcement or proprietary protection (Kotler, 2007).   
Economic factors 
This part is vital for determination of whether the market has a growth opportunity or if 
there are any possible economic restrictions that could cease it. The state is performing four 
types of policies that determine the economic development. These policies are monetary, 
fiscal, income and international trade policy. With the help of these tools the state tries to 
control and set targets for inflation rate, discount rate, economic growth, unemployment 
rate, foreign exchange rate, external balance and others. As they often stay against each 
other it makes it very difficult to fulfil all. It is also important to track and analyse average 
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wages, taxation, consumer confidence or government spending and the attitude of 
government towards foreign investments.   
Social and Cultural factors 
Here it is important to monitor the demographic development such as aging of population, 
level of education and trends in lifestyles and life standards. It encompasses also the rate of 
openness of the society, its habits, traditions, experience, culture dimensions, value 
orientation, and hierarchical needs. To analyse these aspects the Maslow Hierarchy of needs 
pyramid or Hofstede’s cultural dimensions is used. The attitude of society is also influenced 
by several institutions such as state, religion, family and other organisations. These all 
influence the buying behaviour and preferences of the population. 
Technological factors 
This area analyses the technological maturity of a specific country. To the most important 
aspects belong the level of modern technology, the rate of its obsolescence, the percentage 
both of GDP and industry spending on research and development, number of patents 
granted, number of scientists, percentage of households that have access to internet, level 
of Information Technologies (IT) and others.   
The biggest advantages of this model are seen in the enabled understanding of external 
forces that are influencing the company’s strategy and the possibility to evaluate 
opportunities and threats so that company can adapt (CIPD, 2011). Another advantage is its 
very simple form.  It is also seen as an opportunity for a better resource allocation and 
facilitation of risk management. However there are not only positives. It is needed to say 
that it is very difficult to prioritise the most important factors that influence the company 
the most. Anon argues: ‘The higher the likelihood of a change occurring and the greater the 
impact of any change, the more significant this factor will be to the firm's planning’ (Oxford 
University Press, 2007). It is also said that because of the very turbulent economic climate 
the predictions become very uncertain which consequently weakens the reliability of the 
model (Campbell, D., Stonehouse, G. and Houston, B., 2002). Another disadvantage is the 
focus just on external factors influencing the company and does not consider the internal 
factors so it is then needed to add another analysis for example SWOT. It is also very 
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important to focus just on the relevant aspects not to become too complicated so that it is 
not clear what to concentrate on.  
ii. Porter’s five forces model 
The micro environment of a company is determined in majority by four main 
representatives: company, customers, suppliers and competitors. Other subjects such as 
public, state or dealers can be incorporated as well but they are not as important as the 
main four ones. On the contrary of external factors the company can influence these factors 
at least a bit, depending on its strength and sometimes it can even control them fully. It is 
then very likely that it will try to influence this environment so that it is favourable for 
company’s goals. To analyse this micro environment the most common model used is 
Porter’s five forces model. It supposes that the strategic position of a company is shaped by 
five main forces: entry of competitors, threat of substitutes, bargaining power of suppliers, 
bargaining power of buyers and rivalry among the existing players (Value Based 
Management, 2011).  
Threat of entry of competitors 
 This part measures how difficult it is to enter your market. If it is costly and timely to enter 
and compete effectively it is an advantage for the company already operating on the market 
and so it can sustain its competitive advantage more easily. On the other hand if you cannot 
effectively protect your technology and know-how, if there are only a few economies of 
scale, the competitors can come and take the competitive advantage.   
Threat of substitutes 
If your customers can find similar or same product or services on the market easily and it is 
also not costly and timely to switch then the power of the company is weakened.  
Bargaining power of suppliers 
This force determines how strong the suppliers are to influence you. If they can increase the 
price for you or can transfer the cost on you in general they weaken your position. This is 
connected with the number of suppliers for the same articles, the concentration of them, 
the scarcity of the articles, cost and time needed to switch, the threat that suppliers can 
start to operate in the same branch as your company does.  
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Bargaining power of buyers 
The ability of the buyers (customers) to influence you for example in a way of forcing you to 
decrease your price is crucial. It is dependant also on the size of each buyer, their 
concentration, how many does your company have, how easy is to switch to another 
company or how costly it is. In general if you have only a few very important buyers, then 
they can influence you more easily. 
Rivalry among existing competition 
If there are many competitors manufacturing same goods or providing same services, then it 
is very easy for customers to switch from one company to another, because they get always 
the same. If your company operates in this type of industry it has a very little power. It 
cannot influence the prices and not even the quantity. On the other hand if you have a 
monopoly then you can decide on both of these variables. Positive factor is the level of 
differentiation of your product; the higher the differentiation is the more power you get. 
This model can be used not only as a tool for analysis of a micro environment of a company 
but can be also used for evaluation of a strategy implemented. In this case the goal is in the 
evaluation of impacts of this strategy on the change of the five forces influencing company’s 
strength. Although this model is broadly used all over the world and offers many advantages 
it is not perfect. Porter designed this model and stated that it is able to evaluate the 
profitability of the industry (Porter, 1980). On the contrary it is said that rather the company-
specific factors are decisive on the profitability (Rumelt, 1991). When using this model for 
industry other disadvantages reveal. The model suggests the same positions in the industry 
which is not true, because bigger companies have different forces acting on them than 
smaller companies. This is also the case of cartels, strategic alliances and other forms of 
cooperation. To apply this model on a huge transnational company operating in more 
branches of industry it is also impossible to define the specific forces because of its 
complexity. The most significant drawback brings the assumption that the macro 
environment of the company is constant which is definitely not retained. The very frequent 
turbulences and rapid changes are present as suggested in previous chapter. These changes 
are becoming even more frequent and common with passing time. It is then needed to use 
this tool continuously. The graphical illustration can be found in  
20 
 
Appendix 1) 
Picture 4: Porter’s five forces model. 
iii. SWOT analysis 
This model is probably the most used of all. It coheres very closely with the external and 
internal environment analysis and fuses them into one complex unit. The letters refer to four 
basic elements: strengths, weaknesses, opportunities and threats. Thanks to this analysis it is 
possible to detect possible opportunities that are in compliance with company’s goals and 
also to eliminate potential threats.  
The strengths and weaknesses are connected with the internal environment of the company 
where the quality and availability of resources, skills and experience of the company are 
identified. The strengths are positive factors that bring to the company benefits and they 
should be kept and protected. The weaknesses represent activities the company is not 
performing well or the competitors are more successful at.  
The opportunities and threats stem from the external environment of the company including 
both macro and micro environment. The opportunities should not only be utilized but it is 
vital to actively seek for them. On the other hand the company ought to try to find a solution 
to eliminate threats. Preferably the threats could be transformed into opportunities. The 
analytical outputs should then enable the company to create a clear mission and definition 
of strategy for reaching both long term and short term goals.  
Next step should cover the consolidation of all of the four elements and then formulation of 
company’s mission, decision making processes and finally a plan for future. 
The proper elaboration of this analysis should enable the management of the company to 
determine the position of the company against its competitors and to define the proper 
strategy which should be based on the strengths and opportunities and at the same time 
eliminate the weaknesses and threats as much as possible.  
Its big advantage is the very simple and tabular form which makes it easy to orient. On the 
other hand this simplicity brings a threat that it is difficult to fill it properly because it tends 
to a significant degree of subjectivity which is dependant partly on the uncertainties 
scourging the markets.  If we take for example one pricing policy it can be a weakness for an 
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original drug producer while strength for a generic drug producer. There is also a clash with 
assessing priorities to individual aspects so the prioritising should not be left out. These are 
the reasons why it should be accompanied by other analyses such as PEST or Porter’s five 
forces model to ensure the truthful situation. The graphical illustration is in Appendix 2 
Picture 5: SWOT analysis. 
iv. Vision, Mission and Objectives 
Vision can be defined as a visual impression of an entity. It is a motivational message 
delivering a framework for a strategy. It defines the direction of development and it thus 
should be targeted towards the future so that it motivates employees to reach higher 
outputs. It can be imposed on the whole company or only on its divisions.  The vision must 
be communicated regularly so that it is taken as a domesticated matter of fact in order to 
help meet objectives more efficiently. It should mirror the company’s values and culture. It 
defines what the company wants to be in the future, defines its future identity and manages 
to move and coordinate employees in accordance with the objectives. 
The mission is the delivery of a message the company has for its employees, customers and 
all people involved in the operation of company. It has to be in line with the company’s 
values and culture. For a successful formulation of mission it is needed to consider the 
history, interests and objectives also of stockholders, external factors, resources and 
purpose of the company. To be most effective it should be short, apposite and include 
relevant information in order to define responsibilities. 
The objectives should be the results of the vision and mission and should be concrete and 
real. There is a rule which defines the characteristic of objectives named SMART (Jakubíková, 
2008), which say that objectives must be: 
- Specific (it should be clear what has to be achieved) 
- Measurable (company must be able to measure it in order to see if it is achieved or 
not) 
- Agreed (both management and employees must agree with it) 
- Realistic (it has to be possible to fulfil objective) 
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- Trackable (it must be possible to watch the progress) 
v. 7 P’s Marketing Mix 
For different types of companies different emphasises can be stressed on different 
marketing activities. For example a company is manufacturing components for large 
companies and they have only a few customers it would not spend a lot of money on 
marketing. Much more important would be the level of technology. On the other hand 
companies manufacturing consumer’s goods would spend huge budgets on marketing and 
this cost would be the most significant of all. 
The model of 7 P’s is the extension of an original model of 4 P’s, which was primarily 
designed for the goods’ industry (Kotler and Keller, 2007). Hence the importance of services 
has been increasing a modification has been made by adding three P’s. It is used as guidance 
for definition of marketing strategy. The 7 P’s represents different variables that are 
adjusted to generate the best output.  Among these seven P’s there are included Product, 
Price, Place, Promotion, People, Process and Physical evidence. The advantage is seen in the 
flexibility of this model. It can be adapted according to the varying needs of target groups 
and changing marketing environment (Value Based Management, 2011b). These principles, 
including maximising of profit, of the marketing mix are valid also in the case of 
pharmaceutical industry (Metyš and Balog, 2006).  The individual variables are analysed 
below. 
Product 
Product can be divided into three different categories: goods, services and ideas. The 
product itself is according to this model divided into three levels, shown on picture below. 
Picture 1: Product levels  
 
Reference: Anon, 2011c  
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In reference to the core of the product the basic characteristics of the product which meet 
the needs of customers can be mentioned. Among these the physiological characteristics, 
product appearance, shape, taste or power can be named.   
 The second level, total product, is characterised as the ‘differentiation’ of your product. It 
should offer set of additional features that can be seen as symbolic values. These are for 
example the image, modishness, recognition of country of origin and others. These values 
can be and often are much more valuable than the core characteristics. 
The last level refers to what you can offer with the product. It covers all possible services 
such as transportation, installation, after sale services, guarantee, grant of complement 
product etc (Machková, 2009). 
Before entering the market it is essential to adapt the product so that it obeys the valid legal 
regulations (technical norms, hygiene norms, etc.). It is also beneficial to adapt it in order to 
reflect the specifics of individual market, the demand and expectations of customers. This 
involves also the container and the colour.  
The image of the product should be adapted to the needs of demand as well. If for example 
the brand is not well accepted in the specific market it can be sold under another brand. This 
is valid also for the country of origin issue.    
The services are also worth adapting. Each market embodies different claim periods, 
guarantee periods, range of claims and others. Some countries are keen on spending more 
money for above standard services and others just prefer lower price.  
Price 
There are roughly two main factors influencing the price. These are external factors in a form 
of taxation, customs and foreign exchange rate and internal factors stemming from the 
company’s activity (costs, pricing policy, strategic goals etc.).  
From the external factors the most important for a company is the value added tax, 
corporate income tax and social and health insurance. These all influence the price of the 
product as they influence the costs.  
24 
 
It is also important to watch the development on the market, mainly the competitors. If 
competitors decrease the prices the company has to react in order to keep competitiveness. 
Two strategies can be applied. Firstly the company wants to be similar to competitors so the 
prices are set analogous to competitors. When we apply differentiation strategy we 
differentiate the prices from competitors. It can be set both at higher or lower level 
depending on what the company aims at. 
There are several pricing strategies that company can implement when setting the prices of 
its product: 
- Cost-plus pricing 
- Break-even pricing 
- Value perceived pricing 
- Value added price 
- Going-rate pricing 
- Sealed-bid pricing 
The cost plus pricing sets the price according to the costs generated by goods. These costs 
are calculated and then the profit spread is assessed. When applying Break-even pricing the 
price is set according to the desired return on investment in a planned time. The value 
perceived pricing methods takes the expected value of the products to the customers into 
consideration. Value added price is simply adding the value that is created by the company 
during the manufacturing process to finally set the price. When the price is derived from the 
prices of competitors (can be set higher or lower) it is called Going-rate price. The last pricing 
strategy is set in compliance with the price that has been offered by customers for the 
product in a form of bidding.     
In the case of entering foreign markets the company can consider other categories of pricing 
policy (Boučková et al, 2003): 
- Price standardisation (single image, the price is the same for all markets) 
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- Price differentiation ( The price assessment is decided by the affiliated companies and 
is for every market different. However there is a risk of back selling to countries 
where the price is higher) 
- Trade-off strategy (The price is the same in all markets but it is adjusted by certain 
coefficients to fit both the company and the market) 
- Skimming strategy (The price is set differently in time. At first the product sells for a 
higher price and then when the substitutes come it is lowered.) 
- Premium price (This is applied when selling a prestigious product. The customers 
perceive the product as a very luxury product that cannot be afforded by everyone) 
- Penetration strategy (If the company wants to penetrate market in a short time it 
sets very low price and after reaching a specific market share it increase the price.) 
It is also essential to mention the possibility of various additional price benefits in a form of 
discounts, types of financing, possibilities of leasing, providing allowances and others. It can 
be based on the quantity of products sold or single shot preferential treatments. 
Place 
 The key success of a market entering is to be in right time at right place and offer right 
quantities (Kotler, 1997). In the case of international business it is very difficult and costly to 
choose appropriate distribution channels and it affects also other areas of marketing mix. It 
is very important to choose reliable partners.  
The company has basically two ways to deliver its product: directly and indirectly. Direct 
distribution is used when selling a very unique product or when selling heavy machinery. On 
the other hand for consumer goods it is more effective to choose the indirect way via 
intermediaries such as wholesalers, distributors or retailers. In pharmaceutical industry it is 
possible to exert both types depending on the characteristic of an order and customer. 
Usually the direct way is used when the order comprise of relatively large number of sold 
products. 
 There are basically three different types of distribution strategies the company can take 
(Machková, 2009): 
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- Intensive distribution (the company tries to reach as broad range of geographical 
area as possible) 
- Selective distribution (the company chooses the distribution place according to a 
specific factors such as the size of turnover, type of a store or company’s image, etc.) 
- Exclusive distribution (the products are delivered in very limited number of places 
and only via a one specific partner, which makes the product very exclusive)  
The distribution strategy is also influenced by other factors such as consumer’s behaviour, 
level of competition, branch structure, market maturity or local legislation. The company 
should also consider whether it applies a distribution globally or if it adapts the strategy 
according to the specifics of a local market.  
The most rapidly growing distribution channel in last times is the online distribution places 
managed via computers or mobile phones. It is essential then not to forget about these 
ways.  
Promotion 
The basic goal of promotion is to let the customers know about the product, its price or its 
distribution channels. The main question is ‘how?’. Promotion is an essential part both of 
introducing a product to the market and keeping or even increasing its reputation and it 
includes also dealing with new and existing customers. The objective is to broaden the 
awareness of the company and its products services and communicate that the products and 
services offer them value added.  
The chosen promotion strategy is very dependent on the culture of the specific country. 
Different cultures understand the communication message differently, which may cause big 
troubles as it can be understood as something rude or unacceptable. The communication 
channels are also restricted by national laws. This is very common in case of tobacco, alcohol 
and also pharmaceutical products. Not only legal order should be followed but also the 
ethical standard should be respected and also the customer cannot be tricked. 
There are basically three types of promotion strategies when entering foreign markets 
(Machková, 2009): 
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- Global strategy (mostly the same strategy for all markets with only slight changes 
such as translations, media chosen, etc.) 
- Local strategy (fully adapted to local conditions by affiliates) 
- Adaptive strategy (headquarters only sets the message and framework and affiliates 
adapt it to local conditions) 
The company then can choose from three types of communication mix including different 
types of communication activities: 
- Above the line (ATL; they are focused on advertisements in TV, radio, billboards, 
press, etc.) 
- Below the line (BTL; focused rather on merchandising, sales support, direct 
marketing, etc.) 
- On the line (OTL; orientation on internet activities) 
Lately there is a clear trend of big shifting towards the BTL or OTL. 
The communication mix is composed of five main areas that can be chosen by a company. It 
is not important to choose all but only the relevant and suitable ones. The right combination 
is then most effective. According to Hollensen (2007) these areas are: 
- Advertising (newspaper, magazines, journals, directories, radio television, cinema, 
outdoor) 
o The main point is to inform the customer about a product or service with the 
objective of selling it. It should communicate the benefits, why to trust them 
and also the image of a company in general. 
- Public Relations (annual reports, corporate image, house magazines, press relations, 
public relations, events, lobbying, sponsorship) 
o It can be defined as a systematic activity aimed at increasing the trust and 
creation of firm relationship with key public groups meaning building of a 
good reputation in general.  
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- Sales promotion (rebates and price discounts, catalogues and brochures, samples, 
coupons, gifts, competitions, fairs, shows) 
o When the customer is buying a product or service he can receive something 
extra for the purchase which stimulates his taste to repeated shopping.   
- Direct marketing (Direct mail/database marketing, internet marketing, telemarketing, 
viral marketing, showrooms) 
o The aim of this type is to get in contact with the customer and inform about 
the product and services and at the same time create a more stable 
relationship. It is considered to be relatively more specifically targeted. The 
advantage is that it invokes the feedback and answer for the communication 
message. There are also no fees for intermediaries and a company gets a 
clearer image of what the customers want. 
- Personal selling (sales presentations, sales force management, trade fairs and 
exhibitions) 
o In this case the representative of the company deals directly with the 
customers. That makes this tool extremely effective and powerful. However it 
is also very costly but for signing bigger contracts with important customers it 
is essential.  It is the most personal type of communication mix where very 
close and loyal relationships with customers are made which allows the 
company more to understand the customers’ needs. 
There are several factors that affect the selection of specific types of communication mix. 
These can be market maturity, phase of product life cycle ad mostly the needs, culture and 
education of target customers. Least but not last is the fact that it has to count with a 
specific budget that should not be overdrawn. 
People 
It would be a mistake not to include all the people  directly or indirectly connected with the 
product or service consumption process. These include employees, customers, management 
or knowledge workers that are responsible for the reputation of a company. The people are 
considered to be the most important of the whole marketing mix as argued by Anon (2011a) 
 and they represent very significant competitive advantage. The pers
trainings and reach specific standards to maintain a high quality in order to contribute to the 
successful image of the company. They should be able to communicate with the customer in 
a professional way, they should have an aptitude 
and understand what they are selling
general training, sales training and customer service training.
Process 
This area studies the process, including procedures, m
providing a service or consuming of a product. The company should be clear about whether 
the services are appreciated by customers, if they are delivered in time and if customers are 
informed in hand about the services
customer is expecting and imaging when he decides to buy it.
Physical evidence 
This last element of marketing mix is not of insignificant importance. The customers
they intend to buy a product or service
the place where the product or service is being sold. The environment should definitely 
represent the expectations of a customer to create a good image and reputation.
The 7 P’s marketing mix is structure
vi. NPV 
The NPV stands for net present value and is broadly used for appraisal of a long term 
investment. It is the sum of time series of cash flow expressed in the value of today. 
Concerning the cash flows it is counted with both incoming and outgoing cash flows. The 
time value of money is brought by discounting the nominal future cash flows. It is important 
to estimate the discount rate correctly as the result is very dependent on this
result is positive then it is worth to proceed with the investment. 
The formula is:
Where: CF= net cash flow 
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i=discount rate 
n= number of years 
The discount rate is usually calculated as a company’s weighted average capital cost (WACC). 
The formula is:  
 
Where: 
Re = cost of equity  
Rd = cost of debt  
E = market value of the firm's equity  
D = market value of the firm's debt 
V = E + D  
E/V = percentage of financing that is equity  
D/V = percentage of financing that is debt  
Tc = corporate tax rate 
The disadvantage is that this method does not consider the problem of uncertainty after the 
project decision and also the problem with the discount rate which is very sensitive for the 
result. The gap is seen also in the estimated predictions of cash flows which are not very 
likely to be the same in reality since the environment is very turbulent. This is connected also 
with the inflation rate which can vary every year. 
vii. Specifics of Business to Business (B2B) 
The number of customers is lower but they have bigger buying power and then they are 
more important to attract and keep. That is the reason for maintaining very tight 
relationships with customers. The purchase is often performed by professional buyers 
(Kotler and Keller, 2007).   
Other important fact is that the demand is derived from the demand of consumers market. 
Nevertheless when the customers do not need the product then the demand decreases even 
by the companies. It is then vital to watch and stimulate also this market.  
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Other difference is the concentration of customers that is relatively higher which can have 
positive effect on the costs of distribution as there are larger orders delivered too less 
places. 
The decision of purchase is also made having much more information as it is usual that the 
large purchases are agreed by the management of a company and sometimes by specialised 
teams of experts. 
The market research is elaborated on smaller sample but representing bigger portion of 
customers. The negative factor is that the sample is usually very heterogeneous which can 
distort the evaluation of data.  
viii. Marketing mix in the scope of B2B  
As the customers are well informed and are specialists it is crucial to offer detailed and true 
information about for example technical, physiological or physical characteristics. The 
packaging is also very important but in a different way. It is not vital how it looks like but if it 
is practical and complies with the usage. 
Concerning the pricing strategy the rebates and bonuses are used more often and especially 
when the order is for a higher number of products. The demand is less elastic but largely the 
lower price is a tool for keeping a customer too. The price is negotiated by a specially trained 
sellers and experienced buyers sometimes including even the higher management. 
The distribution channels are dependent on the type of product. When selling machinery or 
a sub delivery of intermediate goods the direct distribution channel is used. Otherwise 
wholesalers or retailers are involved.  
The field of promotion is probably the most extensive and different. The usage of ATL 
activities is very limited as they are useless. Probably the only meaningful activity is the 
publication of expert articles in scientific journals, which has a significant impact on 
customers.  
On the other hand BTL activities play a very important role as there are fewer customers to 
ask and it is then less costly for the company. Most used is the personal selling where it is 
important to have a trained staff including also the area of customer care. Very common are 
also direct mailing, telemarketing, sales support activities, fairs and showrooms.  
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Lately the internet is being very popular. This involves advertisement banners, internet 
catalogues, internet pages, marketplaces and etc.        
ix. Segmentation of B2B 
It is important to divide the market into smaller parts, segments, on which it is easier to 
concentrate. The focus on these smaller segments is called targeting (Machková, 2009). The 
most important factors for targeting is the size of market, growth potential, level of 
competition or market attractiveness. 
The segmentation of a market is not as it would be on the consumers market. The criteria 
are not demographic, socio-economic or behaviouristic. The important one is geographical 
where the company focuses its activities on customers in a specific geographical area. 
Second one can be the size. The goal is to divide the market into customer groups according 
to the size, number of employers, market share, size of sales or number of operations and so 
on. Other criterion is the technology where it is important what technological equipment 
does a customer have. After the segmentation the company chooses on which segment it 
targets its activities and effort, which makes it more efficient then. 
x. Competitors’ analysis 
Firstly it is very important to even identify who are your competitors and whether they are 
direct or indirect ones. The main competitors are usually companies coming from one 
specific strategic group bearing a set of common characters such as price and quality level of 
products and services or breadth of portfolio. Members of other groups are secondary 
competitors (Kotler and Keller, 2007). The indirect competitors offer a similar product or 
service that can satisfy the same needs of your customers. 
The positioning of your competitors is also relevant as the company should know whether 
the competitive brand is considered as high-quality, if it is regarded as luxurious or if 
customers feel the price is too high. Then these are compared to their product. 
It is beneficial if you can identify the weaknesses and strengths of your competitors. The 
competitor’s strengths represent a threat which needs to be eliminated and weaknesses 
opens a possibility how to be better and outperform the competitors. 
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Your competitors have specific goals that are essential to know if you want to compete 
effectively as they are connected with the strategy. The objective can be maximising of 
profit, growth or maximising of market share. 
It is vital to estimate the market share of your competitors as you can employ a specific 
strategy then. There is often a market leader who can determine the market trend. Then 
there is a challenger which is the company with second largest market share and that fights 
for the share of the leader. The most companies are followers who just partly copy the 
strategy of the leader as they have an insignificant market share. There are also companies 
that are specialising on niche segments and are mostly not competitors as they are focused 
on different products (Machková, 2009).  
b. Methodology 
There are basically two types of research: the qualitative and quantitative one. The 
qualitative is understood as a process that studies how individuals and groups see, 
understand and interpret world. Other explanation is that it is a research that does not use 
statistical methods and techniques. The researcher tries to see the specific point of interest 
from the perspective of a subject. Neither the number of variables is not reduced nor the 
relations between them. This decision is made by the subjects themselves. The preferred 
ways of this research are open and unstructured research plans and the analysis comes from 
stems from a large bulk of data regarding small number of individuals.  
The differences between qualitative and quantitative research are mainly in the process 
description, relations, circumstances, situation, systems, people, interpretation, explanation, 
exploration, verification of assumptions, theory, evaluation and comparison of practises and 
program innovations.  
The qualitative research studies a specific fact in an entity but also in details. Important part 
is also the involvement of people in the process of understanding and bringing in their own 
interpretations.  The researcher is diving into the reality and becomes its part which causes 
the loss of objectivity. For the process of understanding it is positive but the problem arises 
when trying to pass this knowledge further. It is then essential to separate the results from 
individual persons and try to use it in general with a high level of objectivity.  
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The quantitative method is on the contrary focused on an empirical research of quantitative 
characteristics and procedures and relations between them. The purpose is to count the 
data and use statistical tools to explain the data and make a model delivering the 
explanation. The mathematical expression is very important. Quantitative research is widely 
used and one study showed that this type was used in two thirds of all sociological articles 
published in the top two American journals during 1935 – 2005 as presented by Hunter, 
Laura and Erin (2008). One of the advantages is the higher level of objectivity than the 
qualitative approach as the researcher is not directly involved in the subject matter. On the 
other hand it can miss a context a bit because of that. Generally there is a higher efficiency 
and it can be used for testing the hypotheses. 
i. Research techniques  
Observation 
Observation can be more or less structured and one has to make sure which phenomena 
and how should the observation be done and recorded. It should not be done by anyone 
who does not know all the possible phenomena he could possibly encounter. It is very 
important not to bring in own assumptions, understandings or expectations.  
Experiment 
It is also known as the queen of all research techniques. Firstly the definition of theoretical 
hypothesis has to be made and then the dependent variable must be selected and also other 
independent variables must be determined. Then the independent variables are changed in 
order to give values of the dependent variable.  
Interview 
This technique is a key method when we are interested in opinions, attitudes or beliefs of 
people including employees, business partners, customers or management. It can be also 
more or less structured depending on to what extent we are sure about the topics we want 
to discuss. I case of time demanding interview with prepared successive questions it can be 
named an in-depth interview. However sometimes it is needed and beneficial to use the 
technique of group interview. The interviews and observations can be also with 
questionnaires placed into a superior group of surveys. The disadvantage is that these 
methods allow you to collect just a limited range of data. 
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ii.  Summary of references 
In this dissertation paper there are several types of references used. These references 
include both primary and secondary data. The data has been retrieved from internal sources 
of company ‘F’ and also external databases that the company ‘F’ uses. There has been also 
done a basic research in the company in the form of interviews mainly with the head of 
business unit. Other sources include publicly available data on internet, in journals and other 
professional literature listed at the end of this paper. More specific data needed for the 
analysis of the market were provided by Národní referenční centrum (NRC, 2011)2.  
  
                                                      
2
 Národní referenční centrum is focused on: supporting the emergency bed care sector while implementing 
DRG as a refund mechanism, review of performance lists, using insurance houses’ production data for 
monitoring quality of provided care and training and certification in the area of DRG coding. 
(http://www.nrc.cz/en/home)  
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5. Analytical part 
This chapter applies the models introduced in previous chapter. They analyse the 
environment of mainly the Czech market but also of the Slovak market with the focus on 
company ‘F’ and product ‘A’. The analysis is completed also with other important aspects 
that the models cannot capture. 
It is important to remark that the markets of the Czech Republic and Slovakia are very similar 
and they differ only in few aspects. This phenomenon originates from the very long common 
history as these countries used to be one state till 1993. With respect to this fact the analysis 
will be focused mainly on the Czech market and only the differences are mentioned 
regarding the Slovak market. 
a. Company’s vision, mission and objectives 
The basic and general vision of the company ‘F’ is to help enhance the quality of medical 
care all around the world (Company ‘F’, 2004). To be more specific then the vision is to 
become an important supplier of the parts of medicine where the patients suffer from life 
endangering diseases, mainly in the area of Medication delivery, Renal and Bioscience. This 
vision is supported by three main shared values which are respect, responsibility and results 
which they commit to team members, patients, customers, partners, share holders and 
communities (Company ‘F’, 2004). The vision for anaesthetic market is in accordance with 
the overall vision and includes the vision of being a competitive and important player on this 
market offering variety of high quality inhalation anaesthetics involving high recognition by 
the market.    
The mission is to use its experience in manufacturing of medical devices, medical agents, 
drugs, biotechnological preparations for treatment that will mean a significant difference in 
the patient’s lives (Company ‘F’, 2004). They introduce new technologies to the market 
which will fight successfully the diseases that occur with increasing time much more often in 
the aging population and are thus more consequential. Company ‘F’ also tries to increase the 
health and well-being of citizens, increase the quality of environment, provide free drugs 
where they are needed and support public projects. The product ‘A’ mission includes the 
introduction of the first generic product ‘A’ to the market and support the sale of other 
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already marketed inhalation agents. They want to target all decision makers and penetrate 
hospitals with vaporizers. 
The general objectives follow from the vision and mission. Company ‘F’ ensures in all parts of 
the world as high quality treatment as possible and via its products and services to help 
thousands and thousands of people suffering from severe diseases including haemophilia, 
cancer, immune system disorders or renal disorders every day. The objectives for product ‘A’ 
are both short term and long term. The short term include the successful launch of product 
‘A’ on the market and to reach a significant share. This includes also increased share of other 
already marketed inhalation agents. It involves successful penetration of hospitals and other 
medical establishments with vaporizers in order to provide inhalation agents.  The long term 
target is to increase the share continuously in order to increase the sales of all the inhalation 
anaesthetic agents. The long term aim is to become a very strong competitor for leading 
competitor ‘B’ and to become a company that is recognised as strong in area of all inhalation 
anaesthetics.   
b. PEST Analysis 
Political and legal factors 
The pharmaceutical industry is highly regulated by the government. One of the reasons is 
the fact that the government is the major payer of the health care and drugs. Generally 
there has been a high pressure on lowering the expenditures on health care and government 
is aiming at transferring the costs on pharmaceutical companies by attempting to lower the 
prices and reimbursement. There is also a more significant support of generic drugs which is 
proved by the increase in use of generics by value in 2009 in the Czech Republic by 4.8 % and 
in Slovakia by 8 %. The total share in value is respectively 30 % (Anon, 2010) and 36 % 
(Businessmonitor, 2011).  
The political environment has been very turbulent during last years in the Czech Republic as 
last government was overthrown and replaced by caretaker government for almost two 
years. This has had a negative impact on the whole policy as the laws and reforms could not 
be enforced. The government of these days is also very unstable and faces scandalous cases 
which have very shocking dimensions. The corruption is also relatively high and the lobby of 
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big companies is very strong. This all partly prevents the right steps that should be made in 
order to support the welfare of state and the balanced state budget.  
This all is influenced also by the ministry of health which faces changes even more often. 
There have already been 14 ministers of health (Wikipedia, 2011) since the formation of the 
Czech Republic in 1993. This means that one does not last more than one and half year 
which makes it impossible to implement needed reforms and improvements. Slovakia shows 
a bit more stable environment but still enjoyed 10 ministers since 1993. Nevertheless these 
countries witnessed significant number of important reforms.  
Lately the Czech medical doctors did organise a national strike to increase their very low 
wages and they have been successful. The government promised to increase the wages 
which has been implemented but in some cases this issue still has not been resolved fully.  
The financial crisis has put the government budgets under a huge pressure which results in 
significant governmental reductions in the budget including the area of national health 
system. Slovakia implemented the duty to pay for each visit of a doctor and also for a drug 
prescription. This was then cancelled in 2007 (Novinky.cz, 2007). In the Czech Republic this 
started to be valid later but has survived until nowadays.  
The pharmaceutical market is also regulated by numerous legislative acts including various 
areas such as civil code, commercial code, labour code, consumer protection law, tax and 
financial reporting standards and also regulations of European Union (EU) that were 
implemented after the accession to the EU. The most important is the Medicament law 
378/2007 Sb. that includes also the EU regulations. Very important is the implementation of 
law 2/2009/FAR which regulates the procedure of pricing of medicaments and food for 
special medical purposes. The price order is published on the official web pages of Ministry 
of Health3.  
Another important law, 48/1997 Sb., is related to the public health insurance which is the 
main source of financing the health care including drugs. Ordinance number 54/2008 of 
                                                      
3
 Ministry of health official web site: http://www.mzcr.cz/  
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means of prescription of medicaments enables the pharmacists to change the medicament 
having the agreement of patient for a generic substitute.  
There are several institutions that are responsible for a strict control and regulation of 
pharmaceutical companies. The most important institutions are in the Czech Republic SÚKL 
(Státní ústav pro kontrolu léčiv) and in Slovakia similar ŠÚKL (Štátný ústav pre kontrolu léčiv). 
Firstly the company has to receive licence for manufacturing the drug which is granted on 
the basis of proof of efficacy, safety and effectiveness. These institutions are also granting 
then needed registration for drugs. It is taken as a medical oriented regulation that allows 
usage of a specific drug which is initiated by scientific testing and assessing of a drug 
including own investigation (Zych, 1993). It is considered to be the basic regulation of drug 
consumption. These institutions also decide on whether the drug is registered as Rx drug or 
OTC drug4. They also have supervision over an advertisement that is not communicated via 
radio or TV.   
Another regulation is the setting of maximum price that can be realised. There is also a 
maximal surcharge for distributors. For these decisions is responsible the Ministry of 
Finance. The maximal surcharges are in Table 1: Maximal surcharges - Czech Republic (CZK)  
and Table 2: Maximal surcharge – Slovakia (EUR). The surcharges are digressive which lowers 
the final price and thus saves costs. The ceiling price can be set based on a reference act 
where the price is set as a price of three lowest prices in other states of EU. Very important 
role plays also the Ministry of Health that is accountable for the assessment of 
reimbursement. It sets the height and mean of reimbursement.  
Table 1: Maximal surcharges - Czech Republic (CZK)
 
Reference: Ministry of health, 2011a  
                                                      
4
 Rx drugs are given only with a prescription unlike OTC (over the counter drugs) that can be purchased directly.  
Zone Base from Base to rate
1 0.00 150.00 36%
2 150.01 300.00 33%
3 300.01 500.00 24%
4 500.01 1000.01 20%
5 1000.01 2500.00 17%
6 2500.01 5000.00 14%
7 5000.01 10000.00 6%
8 10000.01 9999999.00 5%
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Table 2: Maximal surcharge – Slovakia (EUR)
Reference: Ministry of health, 2011b    
There are basically two main ways of health expenditure regulation: supply and demand 
measures. To the demand measures it is important to mention the fixing of budgets for 
doctors that has to be fulfilled. Otherwise the sanction is present. This partly favours usage 
of generics.  
To the demand measures belongs positive or negative listing of drugs. When the drug is on a 
positive list it is partly paid by the insurance companies and if it is on negative it is not 
covered. This is crucial for the company as it is very probable that if the drug is on negative 
list it will not be purchased. 
Economic factors 
The most important and most used indicator of economic power is the Gross domestic 
product (GDP). It is beneficial to look at both absolute figures and also at growth percentage. 
This suggests the company how rich is the country and what it can possibly buy. The growth 
than tells us whether it will be more or less in the future. As the health expenditures are 
mainly paid by the state it is even more important for the pharmaceutical companies to 
watch these features.  
Both the Czech Republic and Slovakia shows similar changes in GDP over time. Before the 
world economic crisis the growth was stable and high but sank to even negative numbers 
during the crisis. Both countries have already recovered and have come back to growth 
again. However the pharmaceutical industry is not so much dependent on the economic 
cycles. It slowed down but still recorded positive growth during all periods which was above 
average.  
price limit 
excluding tax
producer 
price limit distributor pharmacy sum zone interval
basic sum surcharge basic sum surcharge basic sum surcharge
0 0 0 14,10% 0 32,90% 0 47,00% od 0,00 do 2,66 
3,91 2,66 0,37 11,10% 0,87 25,90% 1,24 37,00% od 2,67 do 5,31
7,53 5,31 0,67 8,10% 1,56 18,90% 2,23 27,00% od 5,32 do 7,97
10,92 7,97 0,88 5,10% 2,06 11,90% 2,94 17,00% od 7,98 do 13,28
17,12 13,28 1,16 3,30% 2,7 7,70% 3,86 11,00% od 13,29 do 23,24 
28,2 23,24 1,48 2,70% 3,46 6,30% 4,94 9,00% od 23,25 do 39,83 
46,26 39,83 1,93 2,40% 4,51 5,60% 6,44 8,00% od 39,84 do 73,03 
82,13 73,03 2,73 2,25% 6,37 5,25% 9,1 7,50% od 73,04 do 165,97
182,04 165,97 4,82 2,10% 11,25 4,90% 16,07 7,00% od 165,98 do 331,94 
359,63 331,94 8,31 1,95% 19,38 4,55% 27,69 6,50% od 331,95 do 663,88
713,15 663,88 14,78 1,80% 34,48 4,20% 49,26 6,00% viac ako 663,88
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 The rate of inflation is another of the basic indicators of economies. The development has 
experienced little fluctuations but is seen as relatively stable. The long term target is stated 
at 2 %. The Slovak Republic may be in a more difficult position in maintaining the target as it 
is a member of Euro zone and thus has to obey the monetary policy of European Central 
Bank (ECB). The inflation rate is important when looking at the prices in the future as it 
represents the time value of money. This fact is resolved by the discount rate for NPV model. 
The unemployment rate was decreased by massive GDP growths during the last few years. 
However the economic crises depressed the economic growth which resulted in huge 
increase of unemployment even to the long term maximums. The unemployment is worse in 
Slovakia. Nowadays the unemployment rate is decreasing again. Nevertheless for the 
company it could be easier and cheaper to find workforce even though the unemployed are 
mostly unskilled. The problem is also seen in disparities between the education system 
outcomes and the needs of industries.  
The discount rate is different in the countries because Slovakia is the member of the Euro 
zone and has to obey the discount rate set by ECB. The trend in both countries is the same 
during last years. The discount rates have been decreasing to support the economy during 
recession. This represents a chance for companies as they can take cheaper loans and gain a 
more efficient financing of investments.  
The foreign exchange rates are expected to fall in the case of Czech Republic meaning 
appreciation of the Czech Crown. This implicates cheaper buying from abroad. It also 
influences negatively the consolidated financial statements of foreign owners of the 
subsidiaries. In Slovakia the prognosis shows the appreciation of Euro which is similar to the 
case of Czech Crown.  
Very important is also the indicator of government debt related to the height of GDP. Almost 
all countries are experiencing problems to reach balance of expenditures and incomes. This 
puts great pressures on cost cuttings so the company should be aware of reduced 
governmental expenditures which can result in lower reimbursements, lower maximal prices 
and surcharges. On the other hand the promotion of cheaper generic drugs is favoured. 
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As the companies want to control their costs it is important to also look at the development 
and prognosis of average wages. There is a trend of increasing wages every year which has 
to be anticipated when creating a plan of labour costs. The wages are still relatively lower 
compared to developed countries but the relatively more rapid increase forecasts 
diminishing of the wage differences. 
The development and prognosis of all the important macroeconomic indicators in both 
countries is captured in Table 3: Macroeconomic indicators: Czech Republic and Table 4: 
Macroeconomic indicators: Slovakia. 
Table 3: Macroeconomic indicators: Czech Republic 
 
References: Czech National Bank (www.cnb.cz), Ministry of Finance (www.mfcr.cz), National Bank of Slovakia 
(www.nbs.sk), OECD (www.oecd.org), Finance (www.finance.cz), CZSO (www.czso.cz), Ministry of Finance 
(www.finance.gov.sk), Statistical office (www.statistics.sk)  
Table 4: Macroeconomic indicators: Slovakia 
 References: Czech National Bank (www.cnb.cz), Ministry of Finance (www.mfcr.cz), National Bank of Slovakia 
(www.nbs.sk), OECD (www.oecd.org), Finance (www.finance.cz), CZSO (www.czso.cz), Ministry of Finance 
(www.finance.gov.sk), Statistical office (www.statistics.sk) 
Czech Republic 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
GDP (bil. CZK) 2 630,0 2 809,0 2982 3 055,0 2928 2 996,0 3052 3121 3224 3352
GDP growth 6,3 6,8 6,1 2,5 -4,1 2,3 1,6 2,3 3,3 4
GDP per Capita (CZK) 263 000 280 900 298 200 305 500 292 800 299 600 305 200 312 100 322 400 335 200
Unemployment rate 8,96 8,13 6,62 5,44 7,98 9,01 8,7 8,1 7,7 7
average wage (CZK) 18 992 20 219 21 694 22 691 23 488 23949 24600 25600 26624 27689
Inflation 1,9 2,5 2,8 6,3 1,0 1,5 2,1 2,3 3 1,7
CZK/EUR 29,784 28,343 27,762 24,942 26,445 25,290 24,2 23,7 22,7 22,4
CZK/USD 23,947 22,609 20,308 17,035 19,057 19,111 17,767 17,767
government debt/GDP -3,6 -2,6 -0,7 -2,7 -5,8 -4,7 -4,3 -3,5 -2,9 -1,9
Discount rate 1,00 1,50 2,50 1,25 0,25 0,25
Slovakia 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
GDP (mld. EUR) 49 55 62 67 63 66 70 76 81 88
GDP growth 9,20% 11,69% 11,75% 8,86% -5,90% 4,25% 7,09% 7,34% 7,76% 7,79%
GDP per Capita (EUR) 6 931 7 742 8 652 9 418 8 862 9 238 9 893 10 619 11 443 12 334
Unemployment rate 16,16% 13,31% 11,02% 9,57% 12,10% 14,27% 13,60% 12,97% 12,18% 11,48%
average wage (CZK) 573 623 669 723 745 770 798 844 895 954
Inflation 2,71 4,49 2,76 4,60 1,62 0,96 3,52 3,09 3,67 3,70
EUR/USD 1,24 1,26 1,37 1,47 1,39 1,33 1,36 1,30 1,25 1,22
government debt/GDP -0,61 -1,35 -0,71 -1,42 -5,09 -5,56 -2,49 -1,52 -0,88
Discount rate 3,00 4,75 4,25 2,50 1,50 1,25
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Social and cultural aspects 
For common goods it is essential to watch the behaviour of final customers in order to 
anticipate the demand for the products. In the case of product ‘A’ it is not so as it is a drug 
used by medical doctors and nurses only so its demand is even not derived from the final 
consumers demand. It is then not needed even to analyze the cultural aspects of the nations 
precisely. It is necessary only from the point of view of influencers on purchase of the drug, 
especially which techniques to use to persuade the influencers to choose product ‘A’. Both 
the Czech Republic and Slovakia are nations that have relatively stable social environment. 
From the values of Hofstede’s cultural dimensions it can be deduced that the people are 
thinking of only a near future, they like when they are sure about things, they respect men 
more and are based on solid values, they are a bit more individualistic then collectivistic and 
they have respect for authority (Hofstede, 2009).  
 On the other hand the consumption is dependent on the number of anaesthetic operations 
per year. The overall trend in the demographic development is the aging of population. This 
is evident from the Table 5: Demographic development.  
Table 5: Demographic development 
Reference: OECD,  2011  
This phenomenon has a great impact on the consumption of drugs and on the overall 
expenditures on health. This is evidenced by the increased ratio of health expenditures on 
GDP and also by the increase in absolute number of health expenditures showed in Table 6: 
Total health expenditures. This ensures the companies having an opportunity to achieve a 
relatively stable and warranted growth.  
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Table 6: Total health expenditures
Reference: UZIS (Ústav zdravotnických informací a statistiky) www.uzis.cz, OECD, 2011, Health Policy 
Institute, 2009  
Technological factors 
This area is very important for company ‘F’ as it is in majority an original drugs inventor and 
only a minor part of business represents the generics manufacturing. Generally speaking the 
technological demands has been growing rapidly for last decades. The proof is the increased 
cost for developing a drug that rose from 149 million EUR in 1975 to about one billion EUR 
nowadays (ECORYS, 2009a).   
The pharmaceutical industry also holds the first place in R&D demands with the R&D sales 
ratio of 16.2 % (EFPIA, 2010). The manufacturing technology also needs a very high 
technological level as there are strict and precise procedures that the companies have to 
obey as it is implemented in the law. These are the reasons why the companies have to 
generate higher returns. They have to fund these huge investments. This is helped by the 
patents and exclusivities which enable to sell the products at higher prices. 
The technological level of the Czech Republic is higher than the one of Slovakia and both 
have improved much during last years. The Czech Republic can be ranked as a developed 
country in this aspect. Nevertheless the most developed countries still show much better 
results. The R&D expenditures in the case of the Czech Republic reach 1.5 % but concerning 
Slovakia only around 0.5 % of GDP. However the target stated in the Lisbon Treaty is 3 % of 
GDP but almost none of the countries fulfil this criterion. The Czech Republic has also 
applied for 162 patents in 2007 whereas Slovakia only for 42. Slovakia also falls short in the 
number of researchers with 19 814 in 2008 compared to Czech 44 240. The development of 
R&D expenditures, number of researchers and patents applications shows the Table 7: R&D 
expenditures, Researchers, Patents. 
Health expenditures 2005 2006 2007 2008 2009
CR
total expenditures (mil. CZK) 218 774 226 810 241 935 264 520 286 611
percentage on GDP (%) 7,22 7,04 6,84 7,17 7,9
SK
total expenditures (mil. EUR)  2,421.86  2,556.81  2,691.87  3,093.04 3410
percentage on GDP (%) 7,2 7,0 7,3 7,7 8,0
 Table 7: R&D expenditures, Researchers, Patents
 
Reference: Eurostat, 2011  
The main aspects of the PEST analysis are stated in 
Figure 1: PEST analysis - main factors * 
 
* The Czech Republic and Slovakia are very similar to each other so the outc
PEST analysis are valid for both countries they differ only slightly in some aspects: Slovakia 
shows higher business surcharges, higher GDP growth, lower average wage, higher 
unemployment rate and higher discount rate. On the other hand the Cze
and is of a higher technological level. The differences are not of a major importance for 
following estimations. 
R&D 2005
Czech Republic
R&D expenditure (% GDP)
Number of researchers   
Total patent applications 106.42 
Slovakia
R&D expenditure (% GDP)
Number of researchers   
Total patent applications   
Political and
legal
Economic
Social and
Cultural
Technological
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Figure 1: PEST analysis 
ch Republic has fees 
2006 2007 2008
1.41 1.55 1.54 1.47
37 542 39 676   42 538   44 240   
150.21 162.31
0.51 0.49 0.46 0.47 
17 526 18 816   19 375   19 814   
40 754 39.56 42.25
•Highly regulated by government, pressures to reduce expenditures 
•Support of generic drugs
•Many ministers of health in a short time
•Introduction of fees
•Registration needed, marketing authorisation needed, maximum 
reimbursement, distributor's surcharge
•High GDP growth before economic crisis, now grotwth of GDP again
•Pharmaceutical industry relatively not dependent on the crisis
•Relatively stable inflation, relatively low unempoyment, low
governmental debt
•Increasing average wages
•Relatively stable social environment
•Aging population
•Increasing drugs consumption
•Increased costs for developing a drug
•High ratio of R&D
•Relatively high technological level
 
- main factors. 
omes of the 
2009
1.53
0.48 
21 832   
on health
price, 
discount rate, increased
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i. Country’s pharmaceutical business ratings 
It is important to compare the business environment for pharmaceutical companies also 
with other countries to see the attractiveness from an objective point of view. The rating has 
been elaborated by Business Monitor International and is stated in Table 8: Ranking of 
pharmaceutical business environment. 
Table 8: Ranking of pharmaceutical business environment
5
 
 
Reference: Business Monitor, 2011 
From the table it is clear that Czech Republic is seen as a more attractive environment to 
operate in than Slovakia’s environment. Nevertheless both countries are definitely attractive 
to enter as they take the second and eighth rank. The Czech Republic used to be even at the 
                                                      
5
 Scores out of 100, with 100 the highest. 
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top in 2010. The uncertainty of governmental steps and lower pharmaceutical sales has 
taken the first rank (Business Monitor, 2011).   
The Czech Republic’s weakest link is the country’s reward but still embodies above average 
numbers. The negative factor is the low rate of population increase. On the other hand the 
aging population should help the health care spending if the government is able to cover the 
cost. The relatively high urbanisation enables better access to healthcare too. 
This area is also the weakest for Slovakia which even shows below average number. It is 
mainly the negative population growth and relatively high percentage of population living in 
rural areas. In other criteria it reaches above average numbers but lower than the Czech 
Republic. The second weakest is the country risk. 
ii. Porter’s Five Forces Model 
Threat of entry of new competitors 
This threat can be considered as relatively low. The pharmaceutical industry is based on 
modern and sophisticated technologies that require very high investments as mentioned 
before. On the other hand the sector achieves high value added and shows relatively high 
ROI and profit margins which attracts the entrepreneurs.  
The costs are relatively higher also because of a strict regulation of state mentioned before 
too. There are significant fees for patents, registration and marketing authorizations. The fee 
for registration varies from 80 to 120 thousands EUR across Europe as stated by Golikeri 
(2010). The strict rules for manufacturing increase the costs as well. On the contrary the 
relatively immune growth of pharmaceutical industry is a great lure. The growth of 
pharmaceutical industry and industry as a whole is stated in Table 9: Industry indexes.  
Table 9: Industry indexes 
 
Reference: CZSO (www.czso.cz), SSO (www.statistics.sk)  
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Specifically for the product ‘A’ the barrier to entry is represented by the need of providing of 
vaporisers that are relatively expensive. The difficulty is also in the motivation to undergo a 
procedure of replacing the already used vaporiser for different one. 
It is also needed to build a stable and influential relationship with reliable distributors, state 
authorities, hospital management, pharmacists, doctors and others. This takes some time to 
realise and represents thus a big barrier. The successful companies have to reach also 
considerable economies of scale which puts a strain on a large capital investment. The costs 
of marketing and sales also take a significant part of the sales. For the original drug makers it 
amounts the largest cost (ECORYS, 2009b).  
Very demanding is also the manufacturing process which in the case of generic companies 
stands for the largest cost item reaching 51 % of all costs (ECORYS, 2009b). This particular 
industry is also more demanding for the labour costs as the average wages of 
pharmacologists are significantly higher than the average wages in general. The height of the 
wages shows Table 10: Average wages of pharmacologists. 
Table 10: Average wages of pharmacologists 
 
Reference: SARIO, 2009; UZIS (www.uzis.cz), CNB (www.cnb.cz)  
Threat of substitutes 
The threat of substitutes concerning the original drug makers is relatively low during the 
protected life of product by patent which can reach up to 20 years. During this period 
another drugs substituting the protected one cannot be sold. After, the generics are 
introduced to the market at lower prices and the original drug loses its strong positions. 
Sometimes happens that the selling is ceased completely. Regarding the generic drugs the 
threat is moderate. It depends whether the generic enters the market first or not. If yes it 
gains the advantage of a first mover and becomes very strong on the market. There is also a 
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risk of counterfeit drugs (EFPIA, 2005) but in the case of the Czech Republic and Slovakia the 
risk is only a little as there are strict controlling procedures present.  
Concerning the product ‘A’ there are several substitutes represented by all the inhalation 
anaesthetic drugs currently present on the market under the group signed N01AB according 
to SUKL classification. Some are also sold by company ‘F’. Product ‘A’ is though the most 
modern and effective one. It is a generic of already existing original drug sold by competitor 
‘B’.  
Power of suppliers 
This force can be ranked as low. One fact is that the manufacturing companies often 
contracts two or more suppliers for key inputs and ensures regular supplies and also lower 
prices.  
Another fact is the very high concentration of the industry of drug manufacturers. In Europe 
the top 10 % of pharmaceutical companies account for 73 % of total sales (ECORYS, 2009a). 
This reduces the chances of suppliers to deal better conditions considerably. 
Power of buyers 
This power is changing during the last years. To be more specific it is increasing. It is caused 
by the need of cutting the costs of health system. In the Czech Republic and Slovakia the 
state is the one who is paying for the drugs. To be precise the people pays health insurance 
which is then used for funding health care. That’s why there are much higher pressures on 
reducing the prices of drugs via the strict regulations.  
On the other hand this power is decreased by the fact that state and treatment receivers are 
not the ones who decide on the type of treatment or on the type of drugs. It is the doctors 
and partly the pharmacists. So if a patient is given a recipe for a specific drug he just has to 
buy it. The factor decreasing the buyer’s power is also the aging population and more 
frequent illness occurrence in the population. If someone is ill he simply has to be treated 
and take medicaments in order to become healthy or sometimes to even survive so the need 
of drugs becomes vital. 
In the case of over the counter (OTC) drugs the situation is different. Here the demand is 
more sensitive and this sensitivity is even increased as the buyers are more informed and are 
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also experiencing the downturn in what they can afford to buy which reduces the prices too 
(Verbigena, 2005).  
Nevertheless in spite of these increased powers of buyers the average prices of drugs are 
still rapidly increasing. This shows the Table 11: Average price of a drug unit. 
Table 11: Average price of a drug unit 
 
Reference: SUKL (www.sukl.cz), SSO (www.statistics.sk), CNB (www.cnb.cz)   
Rivalry among existing competitors 
As the industry offers significantly higher ROIs and growths it attracts many competitors. The 
return of assets of Fortune 500 pharmaceutical companies reached 10 % while industries 
average only 4.7 % (ECORYS, 2009a).    
The counterpart is the very high concentration in the industry mentioned above which is the 
result of several mergers and acquisitions.  In recent years companies have to pay attention 
also to the danger of parallel trade. The value was estimated to be 4.4 billion EUR (EFPIA, 
2010).  
There is also a phenomenon of first mover advantage that the companies gain when 
entering the market first as they are protected by patents (Verbigena, 2005). And this 
advantage can be even levelled up by possible formal blocking of development of 
competitive products (ECORYS, 2009a).  
In the case of product ‘A’ the danger of parallel trade is relatively very low but the possibility 
to block the development and sales of this generic competitive product can be realized by 
the competitor ‘B’ already operating on the market that is currently benefiting from the first 
mover advantage. There is also another company offering substitutes which makes the 
competitive environment relatively tough and company ‘F’ would have to fight to get 
through.  
The main outcomes of this analysis are stated in Figure 2: Porter 5 Forces - main outcomes. 
 Figure 2: Porter 5 Forces - main outcomes
 
* The outcomes are valid for both countries as they do not show any 
company’s further steps. 
iii. Segmentation and Dynamics of pharmaceutical market
For the company ‘F’ it is vital to watch both in which way the market develops and how 
quickly. Then it can focus just on specific a
Market Segmentation  
At first it is important to state the total amount of sales realised by the pharmaceutical 
sectors regarding drugs. The Czech Republic has definitely higher absolute amount of sales 
than Slovakia with the value of 80.303 billion CZK compared to 1.66 billion EUR
(approximately 40 billion CZK)
GDP is lower in the Czech Republic with 2.19 % compared to 2.47 %
development of pharmaceutical sales is clear from 
Threat of entry
Threat of
substitutes
Power of
suppliers
Power of buyers
Rivalry
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*
significant difference that would influence the 
reas it wants to enter or intensify.
. On the other hand the percentage of pharmaceutical sales on 
Table 12. 
• Relatively low – high investments required
• fees for patents, registration and marketing authorizations
• Vaporizers needed, need of influential relationships
• Demanding development and manufacturing of drugs
• Low to moderate
• Patents
• Danger of counterfeit drugs
•Low
•Two or more suppliers for key inputs
•High concentration of drug manufacturers
• Increased but still low power
• Treatment receivers are not the decision makers
• Illness must be treated
• OTC drugs – bigger power
• Moderate
• High concentration
• High ROI
• First mover advantage
 
 
 
 in Slovakia. The 
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Table 12: Pharmaceutical sales 
 
Reference: SUKL (www.sukl.cz), UZIS (www.uzis.cz), Business Monitor, 2011   
  These pharmaceutical sales can then be divided generally according to three criteria. 
These include the way the drug is purchased, the form of patent protection and division 
according to internationally recognised anatomical-therapeutic-chemical (ATC) classification 
system.  
The division regarding the patent protection includes generic and original drugs whose share 
has been mentioned partly in previous parts. It is important to state that the share of generic 
is higher regarding volume terms but lower when looking at value terms. It is because of the 
lower prices of generic drugs compared to original ones. The shares of individual types of 
drugs are showed in Figure 3. For company ‘F’ it is relevant to consider both generic and 
patented drugs share as it is going to introduce generic drug to an already sold patented 
drug.  
Czech Republic 2007 2008 2009 2010
bn CZK 67,157 72,752 79,75 80,303
% of total health expenditure 28,12 29,01 30,51 29,83
% of GDP 1,9 1,97 2,2 2,19
Slovakia
bn EUR 1,37 1,52 1,61 1,66
% of total health expenditure 32,25 30,79 31,6 31,75
% of GDP 2,5 2,39 2,5 2,47
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Figure 3: Generic and patented drug share 2010 
 
 
Reference: Business Monitor, 2011 
The other division is also important as the company ‘F’ is launching product ‘A’ that belongs 
to the Rx drugs area as it is dedicated only to professionals. The Rx drugs represent the vast 
majority of the market in both countries. The shares are stated in the Figure 4  below. 
Figure 4: OTC and Rx drugs shares (%) 
 
Reference: Business Monitor, 2011 
The last division is the most important one for the company ‘F’. Each drug belongs to one of 
the ATC groups of drugs related to one of the areas the diseases affect. The shares of all ATC 
32%
51%
17%
Czech Republic
Generics
Patented drugs
other
37%
47%
16%
Slovakia
Generics
Patented drugs
other
0
0,2
0,4
0,6
0,8
1
1,2
Czech Rep. Slovakia
Rx
OTC
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groups are stated in diagram. The product ‘A’ falls in the group N (Central Nervous System), 
more specifically to N01AB – the anaesthetics halogenated hydrocarbons. The group N is the 
second largest group in the Czech Republic and third largest in Slovakia speaking about 
volume and value. The trend is positive in the case of value but slopes down when we look 
at the volume terms. Nevertheless the volume terms rise in case of active substance 
contained also in the product ‘A’. The values for the N group and for the subset N01AB is 
reflected in Table 13. 
Table 13: ATC classification: N group sales 
 
*not available 
Reference: SUKL (www.sukl.cz) 
The other very valuable information lies in the knowledge of which companies are present in 
this subset N01AB. This group is formed basically by three mostly used active substances and 
these are product ‘A’, isoflurane and desflurane. Halothane also used to be present but 
nowadays it is not used any more. These are the main substances that are used during 
anaesthesia delivered via inhalation. Isoflurane is offered by all three companies present in 
this area. These include Competitor ‘C’ with Isoflurane, Competitor ‘B’ with Forane and 
company ‘F’ with Aerrane (not present in Slovakia). Desflurane is available only from 
company ‘F’ as a drug Suprane. Product ‘A’ is offered nowadays only by Competitor ‘B’ that 
sells Sevorane. The market shares both in value and volume terms of each company are 
present in Table 14. From the table it is clear that market of Product ‘A’ is dominated by 
Competitor ‘B’ but it embodies stable growth both in volume and value terms. The negative 
factor is that the price is constantly diminishing. Let this trend continue it may cause a slump 
in sales in the future. The market shares for Slovakia are only estimated as the data is not 
available. The estimation is, due to the very similar market, based on the values of the 
market of the Czech Republic. 
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Table 14: Anaesthetic agents - market shares 
 
Reference: SUKL (www.sukl.cz), SUKL (www.sukl.sk), internal materials 
Customer’s segmentation  
A company cannot forget only about the market but also about the customers that should 
be targeted. There are several customers or rather subjects to focus at. These include 
hospitals, other medical facilities, doctors, nurses, management, hospital pharmacies or 
tender committee.  
It is needed to set the criteria according to which the segments are divided. For the company 
‘F’ the criteria are size and the decision making process on choosing the anaesthetics. 
Probably the widest portion of interest should be put on the hospitals as they are the biggest 
medical facilities in the Czech Republic and Slovakia.  
Firstly we should see the development of the number of beds in facilities, number of doctors 
and number of facilities.  From the ‘Table 15: Health facilities (Czech Republic)‘ below it is 
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evident that the number of total beds is steadily decreasing as well as number of beds in 
hospitals. The opposite trend can be seen at the number of physicians which is steadily 
increasing. The number of beds is decreasing mainly because of the governmental efforts to 
reduce costs and to make the health care system more efficient by increasing the utilisation 
of beds. This effectiveness should also be yielded by reducing the number of medical 
facilities that is also evident from the Table 15: Health facilities (Czech Republic) and Table 
16: Health facilities (Slovakia).  
Table 15: Health facilities (Czech Republic) 
 
Reference: CZSO (www.czso.cz), UZIS (www.uzis.cz) 
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Table 16: Health facilities (Slovakia)
 
Reference: SSO (www.statistics.sk) 
On the other hand the number of physicians is increasing as there is a lack of them. Beyond 
these trends the number of beds in anaesthesia is steadily increasing in the case of the Czech 
Republic which is mostly caused by increasing number of operations under anaesthesia. 
Here Slovakia shows an opposite trend. The number of beds in anaesthesia slightly 
decreases. Nevertheless compared to the number of operations the ratio is still higher than 
in the Czech Republic. 
The number of beds in anaesthesiology increased to 914 in 2009 and number of physicians 
was in the same year 711 in the Czech Republic. Even beyond the increasing number of beds 
the bed utilisation is still higher than average with 283 days a year.  
The most important for this segmentation is the number of anaesthesias in specific medical 
facilities. The number of general anaesthesias is increasing steadily every year. In the Czech 
Republic the absolute number is much higher than in Slovakia with 644 007 in 2008 (NRC, 
2011) compared to 147 800 in 2009 (NCZI, 2009). The number of inhalation anaesthesias 
needed for different individual types of operations is stated in Table 17. In this table the 
number of anaesthesias is split between the different types of medical facilities. This 
segmentation data are available for the Czech market only. The Slovakian market is also 
estimated on the basis of values of the Czech market. 
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Table 17: Number of surgeries according to its type (CZ, 2008) 
 
Reference: NRC, 2011 
From these findings the segmentation has been set to cover hospitals from 0 to 100 beds, 
then 100 to 1000 beds and finally over 1000 beds. In the first category there are 18 
hospitals, in the second 124 and in the third 12 hospitals out of which there are 10 faculty 
hospitals concerning the Czech Republic. The last two categories are of the main importance 
and will be approached with highest priority as most of the anaesthesias are realised there.  
Then these facilities will be approached according to the decision making process of 
choosing the anaesthetics used. There are basically four different groups of people that 
decide or have influence on the decision. These are doctors, pharmacists, management and 
the tender committee. Major importance will be given also to the key opinion leaders and 
also partly to nurses. The specific approaches to people are analysed more in detail in the 
following chapters. 
Dynamics 
The positive trend of pharmaceutical expenditures is very clear from the tables stated in the 
previous chapter. The Czech Republic compound annual growth (CAGR) was 6.21 % during 
2007 to 2010 and in Slovakia 6.66 % which is above industry average. The CAGR would have 
been much higher but the last year, 2010, was very weak.  
The prescription drug sales has also risen very rapidly in 2007 and 2009 but in 2009 it faced a 
downturn of 0.6 % in the Czech Republic and Slovak Republic showed same trends (Business 
Monitor, 2011). Patented drug sales embodied similar double digit growths in 2007 and 2008 
as the prescription drugs but in 2009 and 2010 turned to negative numbers of - 2.2 and - 4 % 
in Slovakia and - 0.8 % in both years in the Czech Republic. The CAGR of patented drugs was 
7 % in the Czech Republic and 2.6 % in Slovakia. The generic market developed a bit 
differently and did not reach negative numbers at all. The growth was in 2010 5.4 % in 
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Slovakia and 2.3 % in the Czech Republic. The CAGR of generics sales was unbelievable 11.4 
% in the Czech Republic and very interesting 7.9 % in Slovakia. The individual CAGRs are 
stated in Table 18. From this it is evident that the generics are taking a larger share against 
the patented drugs.    
Table 18:CAGR of drug market 
 
Reference: Authors calculations from previous tables 
iv. Evaluation of analysis of micro environment 
The following table includes the quantitative summary of the Porter’s five forces model so 
that it is clearer to see the position of company’s ‘F’ business. It contents also the main 
driving forces influencing the individual powers in more transparent way. The quantitative 
evaluation is stated in Table 19: Quantitative evaluation. 
Table 19: Quantitative evaluation 
 
* This quantitative evaluation is valid for both markets as the differences between the two 
countries do not significantly influence the further steps of the company. 
From this table it is clear that there is a very significant possibility for company to be 
successful as it scored almost 65 % which can enable stable and sustainable growth of sales 
Forces Negative Average Positive
Points*Weigh
t
Weights 0 1 2 3 4 5 6
Threat of new entry 5 x 25
Competitive rivalty 6 x 12
Supplier power 3 x 18
Buyer Power 4 x 16
Threat of substitution 5 x 10
Market growth 4 x 24
Received points 105
Maximal total points 162
Evaluation 64,81%
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in the future. The weakest links in this imaginary chain represent competitive rivalry and 
threat of substitution. On the contrary the market growth has been very strong and the 
power of suppliers is very low.  
Table 20: Main outcomes of company’s micro environment 
 
v. Competitor’s analysis 
From the market segmentation stems two main relevant competitors to company ‘F’ that 
operate on the market of inhalation anaesthetics. One is considered to be the direct 
competitor but in this case it is not a proper direct competitor. The company Competitor ‘B’ 
is offering the same drug but as an original one so it is not a direct substitute and the second 
company Competitor ‘C’ is offering a slightly different drug suited for similar purpose so it is 
also considered as a substitute but not direct. 
Competitor ‘B’ 
Competitor ‘B’ is one of the biggest pharmaceutical companies in the world and has very rich 
history going down to the 19th century. It employs around 72 000 (Competitor ‘B’, 2011) 
employees all over the world. It is focused mainly on five different areas including Diabetes 
care, Diagnostics, Nutrition, Molecular and Vascular areas. From the 1997 it is present on 
also on the Czech market where it employs 200 people in the field of marketing, sales and 
administration.  
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In the field of inhalation anaesthetics it is definitely a market leader with very rich 20 years 
long experience of marketing Product ‘A’ and others. Nevertheless there occurs a special 
feature. In fact it did not invent the Product ‘A’ but just bought it indirectly through one 
Japanese company from company ‘F’.  
Its world market share in the whole world is 81 %6 which is reached by a very strong focus on 
the field of inhalation anaesthetics. They also possess a very strong marketing and sales 
force size and are engaged in a very high percentage of vaporizers penetration in hospitals. 
The renting of vaporizers by Competitor ‘B’ to hospitals and other medical facilities formed a 
very strong barrier to enter this market. They have also built a very close relationship with 
customers and they then become very loyal which increases the barrier even more. They 
also succeeded in creating a very strong and positive brand image and they strongly 
differentiate and leverage branded drugs against the generic drugs. The main goal is to keep 
the market share and to maintain the market leadership position.  
The other phenomenon is the strong effort to convert the older anaesthetics such as 
Isoflurane and Desflurane to Product ‘A’ which limits the market of Suprane sold by 
company ‘F’. The other strategy is the decreasing the prices of older generics when it is 
demanded. They also try to raise doubts about the quality of generic drugs. This all is done in 
purpose of preventing the competitors to come and it can be anticipated that they will 
continue in this strategy. They will also innovate and rationalise they portfolio according to 
the current demands of the market. It can also be expected that they will be willing to 
decrease the price of Product ‘A’ in order to keep the market share. 
Competitor ‘C’ 
This company coming from India is much smaller than Competitor ‘B’ and has also much 
shorter history but in India it is one of the biggest pharmaceutical companies and offers one 
of the largest product portfolios. It is focused mainly in nine key therapeutic areas including 
the Cardio-vascular, Neuro-psychiatry, Oncology, Diabetes Management, Respiratory, Anti-
infectives, Gastro-intestinals, Dermatology and NSAIDS (Competitor ‘C’, 2011).    
                                                      
6
 Internal materials 
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Unlike Competitor ‘B’ it represents the low cost alternative to brand drugs. It can offer very 
cheap price as the manufacturing costs are significantly lower in India. At the same time the 
quality of the drugs has improved a lot. They gained the knowledge and access to the drugs 
through various mergers, acquisitions and joint ventures.  
It is the only company that offers all types of inhalation anaesthetics. In case of the Czech 
Republic and Slovakia it offers only the Isoflurane and thus takes only a minor market share 
but still much more significant than company ‘F’.  
Its main goal is to become an important player on the Czech and Slovak market. They have 
relatively strong marketing and sales base. They have built a strong partnership with 
distributors, which creates a better position for them and they also apply the strategy of the 
low price. 
They also bid aggressively in strategically important tenders and  increase the investment in 
vaporizers to reach higher market share. Competitor ‘C’ gain the market access through B2B 
deals. It also attempts to build a relationship with customers to gain the confidence as a 
relatively new name in anaesthetics. The intention of Competitor ‘C’ is to introduce a drug 
based on active substance of Product ‘A’ but they will not manage this before company ‘F’ 7. 
They will probably also try to arrive with also B2C deals.  
vi. SWOT Analysis 
This part is summarising the strengths, weaknesses, opportunities and threats that partially 
stem from the previous analyses and also from the specifics of company ‘F’ and mainly its 
new product ‘A’. 
Strengths 
There are many strong attributes that product ‘A’ and company ‘F’ possess. Firstly it is 
important to say that the price, as product ‘A’ is a generic drug, is lower than the original 
Product ‘A’ offered by Competitor ‘B’. Another very strong factor is the fact that company ‘F’ 
can offer the whole portfolio of inhalation anaesthetic agents including Product ‘A’, 
                                                      
7
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Isoflurane and Desflurane.  Strength lies also in the early expected date for the launch of 
product ‘A’ which is set for autumn 2011. 
The other strong aspects are more of chemical and usable qualities of product ‘A’. The 
bottles in which the product ‘A’ is kept are made of aluminium which brings a lot of 
advantages. The bottle is very resistant to damages and it prevents the drug from 
decomposition by light. It also does not contain the Lewis Acid that causes the substance ‘A’ 
to decompose too and thus less water is needed to store this substance.  
It is very beneficial that the minimal alveolar concentration (MAC) that is needed to 
narcotize the patient decreases with the age so for example for older people it is needed half 
of the concentration than for the young ones. It is also low soluble in water and thus only a 
minimal amount is dissolved into blood. There can also be seen a very rapid increase in 
alveolar concentration compared to the inspired concentration and the efficacy starts within 
one minute.  
The substance is eliminated via lungs very quickly too. Also the depth of anaesthesia is 
following the inhaled concentration. Very positive is also the fact that it does not increase 
the heart beat under the concentration lower than two MAC. Another benefit is the quicker 
time to emergence, responses to command and lower analgesia. Product ‘A’ is also non-
pungent which means that it does not invoke respiratory irritability. 
The process of the manufacturing ensures the highest quality as it is made by a three step 
process of manufacturing. There is also an additional granting of highly modern and quality 
vaporizers including their service and life time warranty. The installation of these new 
vaporizers is very quick and it takes only 20 minutes to change the old vaporizer for a new 
one. The aluminium bottles can also be mounted to a special easy-fill cap which ensures that 
no product ‘A’ is wasted and if it is not used all it can then be stored for later. The time for 
storage is also very useful as it can be stored for 24 months. The product ‘A’ is also AN rated 
that means that it has the same efficacy and same side effects as the original drug. 
Other strengths follow from the previous analyses. These are: the high number of facilities 
where Product ‘A’ could be used, the 70% share of Product ‘A’, low power of suppliers and 
buyers and highly similar Czech and Slovak markets where same strategy can be used 
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Weaknesses 
To the biggest weakness it should be stated that the product ‘A’ needs for usage a new 
vaporizers and the penetration of vaporizers from company ‘F’ is very low so the trump is in 
the hands of Competitor ‘B’. This is evident from the previous analyses from which follows 
also the high rivalry among current competitors. The vaporizers are also very costly to 
purchase for every medical facility by company ‘F’. Another negative factor is the low 
presence in the market of inhalation anaesthetics and also the low focus on this area by the 
company ‘F’. Weakness is also the already mentioned need of creating influential 
relationships with customers. 
It is also needed to ensure an open access to air inflow, keeping the patient’s inspiration, 
artificial ventilation, oxygen enrichment and also the circulatory respiration. It is also 
important to say that the product ‘A’ can cause a malignant hyperthermia and for the 
patients with renal insufficiency the safety is not guaranteed.  
There is also a danger of presence of strokes, bronchospasm, laryngospasm and also cough. 
Product ‘A’ is also not suitable for patients with subject to heart arythmia or neuro-muscular 
disease. Also when product ‘A’ react with NaOH or KOH another substance can be formed 
which is toxic. Nevertheless the toxicity has never been high enough to cause harm. Also 
with the higher flow of CO2 the temperature rises. Last but not least it decreases the blood 
pressure when subject to higher concentration.  
Opportunities 
There is a huge opportunity as the patent protection of branded Product ‘A’ is expiring soon 
and company ‘F’ is going to be the first to introduce generic to the market. There is also a 
very strong usage of Product ‘A’ in the market which is seen even to be higher and also to 
convert from other inhalation anaesthetic agents. The market is also expected to raise 
demand for the generic Product ‘A’.  
What more there are other positive factors that favours product ‘A’. These are the increasing 
expenditures on health, aging of population meaning more operations needed, increasing 
number of beds in the area of anaesthesiology and the higher volume of anaesthetics used. 
What more company ‘F’ is also present on the market of inhalation anaesthetics even now 
which provides it with significant experience in sales and marketing.  
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There is also an effort from the government to reduce the expenditures which favours the 
generic drugs and there is also an opportunity to increase the market share of Isoflurane and 
Desflurane.  
Threats 
The biggest threat is seen in the very high barriers to enter this market caused by the high 
presence of vaporizers of Competitor ‘B’. All the key customers are nowadays supplied by 
Competitor ‘B’ vaporizers which also increases the loyalty of the customers to Competitor 
‘B’. There is also a threat that Competitor ‘B’ will reduce the price of Product ‘A’ in order to 
keep the market as it has done in the US. This price decrease can also lead into a price war.  
There is also a threat that the costs to maintain the vaporizers will be too high. It is also 
possible that a new generic Product ‘A’ can come which is intended by the competitor 
Competitor ‘C’. What more another original inhalation anaesthetic can be invented which 
will change the market very significantly.  Also the maximum price and reimbursement can 
be lowered by the government. 
There is also a risk by proteinuria and glycosuria when the concentration exceeds 2 MAC and 
at the same time the circulation is less than two litres per hour. There is also the risk of 
forming of the toxic substance mentioned above. There is also a small doubt about the non-
transparent aluminium bottle. The product ‘A’ also contents 50 times higher concentration 
of HFIP but it is still not of a clinical importance. There is also a possibility of presence of 
disseminated sclerosis from the residual anaesthetics but it was not proved to be caused by 
product ‘A’.  
The main outcomes of SWOT analysis are presented in table. 
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Table 21: Main outcomes of SWOT analysis
 
vii. 7 P’S Marketing Mix 
In this chapter the company’s marketing mix is analysed. It consists both of the analysis of 
the product ‘A’ specifically and also of the marketing mix used by a company ‘F’.  
Product 
As it is mentioned in the theoretical part the product can be seen as it is composed of three 
parts. Firstly the core product is analysed followed by the total product including 
differentiated characteristics and finally by the augmented product including services 
provided. 
Company’s ‘F’ main focus is on developing, manufacturing, marketing and finally selling of 
pharmaceutical products mainly in the area of Medication delivery, Renal and Bioscience. In 
this case we can leave out the developing and manufacturing as it is not in question talking 
about the Czech and Slovak subsidiaries. The main articles of this company include original 
drugs. Nevertheless the product ‘A’ is a generic drug to an already existing one and it 
belongs to the group of inhalation anaesthetic agents more specifically halogenated 
hydrocarbons with the ATC code N01AB08.  
It is used for an induction and maintenance of general anaesthesia in adults and children. It 
shows better results and characteristics than other older anaesthetic agents as seen in the 
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SWOT analysis. Product ‘A’ is a halogenated methyl isopropyl ether inhalational anaesthetic 
which produces a rapid induction and recovery phase. It is a clear, colourless liquid stored in 
aluminium bottles lined with an internal epoxyphenolic resin protective lacquer, and plastic 
screw-on caps with a polytetraflurorethylene (PTFE) laminate inner liner. The bottles are of a 
volume of 250 ml (SUKL, 2011). It can be sold as separated bottles or as a pack of six. The 
label of the aluminium bottle is yellow. The bottle can be seen in appendix 4 in Appendix 4) 
Picture 7: Product ‘A’. This medicinal product comprises only of the active substance with 
minimum amount of water. The bottles do not require any special storage conditions. The 
cover of the bottle contains all the information required by law and is in accordance with the 
law both in the Czech Republic and Slovakia. 
Product ‘A’ should be administered with a vaporiser calibrated specifically for product ‘A’ 
and with the use of a filling system with a key which is designed for the product ‘A’ special 
vaporiser or other filling systems suitable for the product ‘A’ special vaporiser (SPC, 2009). 
An example of a vaporizer is shown in the Appendix 5 Picture 8: Vaporizer.  
The product cannot be purchased by patients and it can be used only by certified medical 
doctors or nurses. The pure liquid in a bottle is poured into a vaporizer which transforms it 
into a vapour that is then inhaled by the patient. It is very important that the 
anaesthesiologist know the right concentrations and indications needed. The product ‘A’ has 
the FDA approval meaning that is therapeutically equivalent to the branded product and 
provides also the same critical versatility.  
The second very important thing represents the total product. The product ‘A’ as having the 
FDA approval offers a very good economic value as it is cheaper than the original drug. The 
anaesthesiologist can be confident that they provide high quality care for patients and they 
can thus feel good for having made a responsible and sensible choice which decreases the 
demands on budget.  
It is also very important not to forget about the fact that the company ‘F’ is the original 
inventor of the drug so others can rely on the quality. The lower price also opens an 
opportunity to start using a high quality anaesthetic agent in a higher number of cases 
including new uses or broadening of the already existing ones. The use of aluminium bottles 
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offers a much more practical handling and reduces the risk of breakage. The easy fill caps 
also make the handling and using easier which increases effectiveness and saves time. 
The last is augmented product and it includes the services. Company ‘F’ is not only 
purchasing the product ‘A’. It also secures and pays for the most modern, efficient and 
accurate vaporizers. They do this by contracts with manufacturers of the vaporizers. 
Currently there are two suppliers of vaporizers that company ‘F’ has. Not only the vaporizers 
are secured. Company ‘F’ also provides the installation and maintenance of them. The 
vaporizer cost is relatively high and so are the maintenance costs. With these costs is 
counted in the NPV model.  
The company ‘F’ also can offer the possibility of supplying all of the types of anaesthetic 
agents in one pack which is a very effective way for customers to secure needed types of 
anaesthetic drugs so that they can choose the proper one and increase the quality of care of 
patients.    
Price 
As company ‘F’ is mostly the manufacturer of original products it mostly sets the price 
according to the cost-plus pricing method. In this price the costs for research and 
development of the drug has to be counted so the final price is very high compared to 
manufacturing costs. It is definitely needed to also consider the Value perceived and Going-
rate pricing method as sometimes there are similar original drugs on the market or the 
product is prestigious enough to set higher prices. 
In the international point of view company ‘F’ then mostly uses the skimming strategy or 
premium price strategy. As there are no substitutes on the market when the drug is 
protected by a patent the company can set very high price and then when the patent expires 
and other generic drugs come it has to lower the price in order to keep the sales. During the 
patent protection the strategy can be also the premium pricing strategy as there are no 
substitutes.  
In the case of product ‘A’ the pricing strategy has to be very different. As there is already a 
original drug on the market the company ‘F’ has to consider the going-rate price strategy 
and set the price according to the competitor. The goal is to set it lower than the competitor 
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as it is perceived as not as prestigious product as the original one. This is connected with the 
value-perceived pricing strategy too. Definitely the company has to also watch the cost-plus 
pricing not to set the price below the height of costs so that it would make loss.  
It is also important to take into consideration the relatively low price elasticity of this type of 
drug. It is so because the drug is needed even if the price is higher as it does not have many 
possibilities of substitution as the other anaesthetics have different properties and are 
suitable in different cases. 
First of all the company ‘F’ has to deal the maximum price with the state health authorities. 
Nowadays there are talks about setting the maximum price at the same level as the 
manufacturer price which contains the costs plus certain profit of manufacturers so 
currently the price is seen to be 4,180 CZK for the 250 ml bottle of product ‘A’ and 25,080 
CZK for the pack of six 250 ml bottles. The competitor has not set the maximum price and its 
manufacturer price is 4,600 for 250 ml bottle. This price does not include value added tax 
(VAT).  
It would be crucial to set the price lower than the competitor. It is estimated that the price 
has to be at least 10 % below the price of the competitor. This means that if the price was 
set at current manufacturer prices it would reach this goal.  
The company has to also see and project the future trend into the price too. As it is 
mentioned above that the companies selling original drugs practises the skimming strategy it 
can be expected that Competitor ‘B’ will decrease the price continuously to compete against 
the new generic drug. Also the company ‘F’ has to adopt this trend in order to keep the price 
below the original drug price in order to keep or even enlarge the sales.  
Other very important factor to watch is the development of the value added tax. The drugs 
are now in the lower tax rate regime so the rate is 10 %. Nowadays when the government is 
trying to decrease the state deficit a change has been proposed. The tariff should be 
increased to 14 % in 2012 and later the two tax regimes should be united to just one with 
tariff of 17.5 % in 2013 (Zdravotnické noviny, 2011). This increase will result in increase in 
final prices which can possibly decrease the sales slightly. 
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It is also important to look at the business surcharge which also influences the final price. If 
the surcharge of distributors or pharmacies increases the final price will also increase which 
can then negatively influence the sales. Nevertheless this trend is very unlikely to take place 
as this would not bring any money to the state budget but will even take more money out as 
this profit goes to private hands. More probably the decrease can be expected as the savings 
are on the list nowadays.  
Place 
The pharmaceutical products get to the market usually via numerous mediators. In the field 
of drugs business there is an indirect way with usually two mediators. The supply chain is 
well described by Picture 2: Pharmaceutical supply chain. Firstly the drug is developed and 
then manufactured by the developer itself or it can outsource the manufacturing to contract 
manufacturer. Then because the number of supplied sites is very big it is necessary to use 
the wholesalers that are specialized for this purpose which results in cheaper and more 
effective distribution. Then the distributors sell this drug to medical facility where it is 
consumed or it sells it to a pharmacy where the final customers buy it. It depends on the 
type of drug how, when and where it is finally consumed. Sometimes it is difficult to see 
what the distribution channel is like and whether it is appropriate.   
Picture 2: Pharmaceutical supply chain 
Reference: Zhang, He and Tan, 2008 
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In the case of product ‘A’ the last part of the chain, the consumer, is participating in the 
supply chain only passively as he does not decide on the purchase of the drug. He only 
receives the treatment. The drug is then purchased by medical facilities such as hospitals or 
health centres. The decision then can be mainly in the hands of anaesthesiologists, the 
hospital pharmacy or the management of the medical facilities, in this case mainly regarding 
hospitals. It is thus very reasonable to concentrate just on these targeted groups regarding 
the distribution. The drug stores and ordinary pharmacies are totally ruled out in the case of 
product ‘A’.  
As the company ‘F’ is mainly the developer and manufacturer of drugs it uses the 
wholesalers as connecting links. It is thus crucial to concentrate on the distributors and 
create and keep narrow relationships with them. It is very important also to choose reliable 
and high rated ones with plenty of experience of the market.  
The distributors can in the case of product ‘A’ apply a selective rather than intensive 
distribution policy as explained in the theoretical part. The distributors should concentrate 
only on customers that will buy larger quantities of the drug packages. It is so because the 
price of a needed vaporizer is relatively high so the company needs to repay for it. Also not 
all the medical facilities perform for example surgeries under general anaesthesia.  
There are also cases when the manufacturer can skip the connecting link and sell the drug 
directly to medical facilities. These situations can include the purchase of drugs that are 
subject to tenders because they exceed certain amount of total costs. In these the 
manufacturer can afford to secure the distribution by itself because the order is of a very big 
volume so it is worth it.  
In the case of these direct sales the company ‘F’ should also pick a selective strategy and 
supply only tenders above a certain amount of ordered units. Otherwise it would be too 
costly to supply each customer with low number of units. It is thus beneficial to watch 
mainly all the tenders and take part in the active participation. The company targets not only 
the distributors but also the medical facilities itself. 
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 Promotion 
The company ‘F’ is an affiliate of the mother company based in US. The promotion strategy is 
in general proposed by the mother company. It recommends the main message and 
framework which should be applied and also the communication mix. Nevertheless these 
can be adapted and modified to fit the local market. So the affiliates apply the adaptive 
strategy as explained in the theoretical chapter above. Only the fundamental and big 
changes should be addressed to the mother company that should approve it. The adaptation 
is often needed because of the national regulation of propagation. For example in the Czech 
Republic and Slovakia mainly the ATL activities are very restricted by the Advertisement law 
(Zákon č. 40/1995 Sb.).  
Company ‘F’ uses all of the three types of propagation activities including ATL, BTL and OTL. 
This is because it sells both OTC drugs and Rx drugs. In the case of drugs that are intended to 
customers being also consumers it uses ATL activities including TV, billboards and other mass 
media. As an example the billboard advertisement for encephalitis can be mentioned. See 
Appendix 6 Picture 9: Billboard advertisement. There is also a TV commercial giving you 
notice about the encephalitis.  
Other propagation channel used from the ATL category is the advertising in magazines and 
journals. This includes the advertisement both for general public and also for professional 
public. Company ‘F’ is very active in publication of various articles dealing with different 
types of illnesses which is very effective channel of propagation itself.  
The company ‘F’ is also active in the field of OTL. It has its own web pages which are used as 
a matter of propagation. They are not intended for purchases. The pages contain basic 
information about the company including products and services but you can find there also 
information about health which is related to the products the company offers. Beyond this it 
is also engaged in other web pages that are related to health. On these pages you can find: 
what is new, general description of the disease, what can cause it, how to protect ourselves 
and other similar type of useful information. An example is the web page 
www.pozorkliste.cz. These help to build positive PR and enhance the brand awareness. 
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In spite of the active participation on these the main focus is though on the BTL activities. As 
most of the drugs are prescribed by medical doctors or purchased by medical facilities, 
which means lower number of targeted customers, it is vital to focus on this area.  
Every single pharmaceutical company in this area includes the presentation of drugs directly 
to medical doctors by sales representatives. This is supported by propagation materials such 
as leaflets, handouts, brochures, advertisement gift items and others. It is important to 
mention that the gift items are limited by maximum value for one person per year 
(Nováková and Jandová, 2006). Very common are also visits on site where the sales person is 
obliged to transfer the information regarding efficacy, maximum price, reimbursement and 
others about a drug so that the intended person is able to create his own opinion (Law no. 
40/1995 Sb.).  
Other tool is the organising of professional symposia that are attended by doctors. These 
symposia are very often accompanied by refreshments, cultural events or sport events. 
These activities are also regulated by law. Very similar is the support of congresses that can 
be local, regional or international. The support on these congresses is also regulated by law.  
The company ‘F’ also makes use of supplying doctors with free samples of drugs. This area is 
regulated as well. The samples have to be given only to persons that are eligible of 
prescribing or delivering the drugs. The amount has to be maximally the smallest package 
offered by the company and has to be signed as a ‘free sample’. 
Other way of propagation is the direct marketing. Company ‘F’ uses this too mainly in a form 
of electronic means such as direct mailing and sometimes telemarketing. The content of the 
mail is mainly about new products, events and special offers. The company ‘F’ applies this 
mainly in case of already existing customers. It can be used also for new customers but the 
impact is significantly lower. 
Thanks to these activities the company can reach very close and loyal relationships with the 
persons that have the most significant influence on buying the products. The wholesalers 
and distributors are also not left out as they are very important too. The representatives of 
the company are dealing with them to set better conditions and prices for sales. 
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As the product ‘A’ is a generic Rx drug the mean of propagation should stem mainly from the 
BTL and OTL propagation strategies. The ATL can be applied too but mostly in a form of 
scientific articles and propagation in scientific topic-related journals.   
People 
The people are the most important factors of all as stated in the theoretical part. There are 
many different groups of people involved in the process of buying the anaesthetic drug 
meaning both the representatives of a company, the customers or mediators.  
For the company ‘F’ work many people in different departments. The most important 
departments for successful sales of a product are sales and marketing departments. There 
are two key positions for each drug: key account manager and product manager. These are 
the ones responsible for dealing with customers and for sales of individual products. Very 
important is also the support of the management. This is more important when the deal is of 
significant value. These situations encompass mainly the tenders.  
It is important that the people working in these departments have strong interpersonal and 
communication skills. They must also know the products very well in order to vindicate the 
advantages and positive values of the drug. In order to achieve these skills and capabilities 
regular and intensive trainings are needed to be taken. Very important is also the 
communication between each department so that the company can operate as one unit and 
be thus effective. 
In the case of distributors and wholesalers the most important human resources are coming 
from the team of business consultants that are responsible for dealing of prices, conditions 
of purchase and special offers. They also transfer the product to retailers, mainly 
pharmacies. They can also offer marketing services via marketing consultants both to 
manufacturers and retailers.   
On the side of customers and buying decision influencers we can mention three different 
groups of people. To the first one belong the anaesthesiologists and anaesthetic nurses that 
decide on the type of anaesthetics used during a specific operation. The second group 
includes the pharmacists, general public offering (GPO) contractors and tender committee 
that represent the purchasing authority. They seek for reliable suppliers and they also 
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control the budget. In the last group stand director of pharmacy, chief of anaesthesia, 
director of contracting and the tender authority. These are the ultimate decision makers on 
drug procurement.  
Process 
The process of buying a drug is relatively complex and there are many turning points that 
determine whether the specific drug is finally bought or not. The buying process is clearly 
seen in picture 4. 
Picture 3: Buying process 
 
Reference: Internal materials 
Firstly the company has to enter the market entry access point. In the case of drugs there 
are five different types of market entering. These are tenders, general public offerings, 
attempt to overtake Competitor ‘B’ existing contract, calling the customer directly by 
representative or via the commercial team account presentation.  
Then there is the phase of evaluation and diagnosis where the customer stays as he was 
before or chooses different possibility. After, the potential contract is reviewed and it is 
ruminated over a product trial. Next step is usually the choice of the customers whether 
they choose sole award or if they go for dual- or multi-award. This means that if they choose 
sole award they will buy the drugs from one company only.  
76 
 
After this step the brand choice and dosage take place. This is very important as the 
customer chooses the company he will buy from and also the quantity. If they choose the 
company ‘F’, the fulfilment proceeds. There is a question whether company ‘F’ has the 
amount in stock. If not the wholesalers and distributors take part and if there is enough on 
stock the purchase is direct.  The last phase is so called persistence as it is important 
whether the fulfilment was successful. Whether the customer is satisfied depends on the in 
time delivery and the quality of service offered and others. The customer satisfaction is 
crucial for future sales and for building a wanted long-term relationship. 
Physical evidence 
The last part of this marketing mix is measuring and characterising the overall environment 
of the sale. It is important that the company ‘F’ ensures high quality of the sales and 
marketing team so that the customer feels that company ‘F’ is the right choice for supplying 
the drugs.  
The physical evidence of company ‘F’ is also created by the high level, well-arranged and 
well-designed web pages. The company has a uniform framework for invoices, despatch 
notes or letters. They use the same style and there is always the same colour combination 
with the logo at the top. Similar rules are valid also for the brochures and other propagation 
materials. The company also disposes of very luxury offices in business centres located near 
the centre of Prague and Bratislava.   
This area covers also the packaging of the products and quality of service provided. It is also 
very important to secure this high quality and reliability at the side of wholesalers and 
distributors. These all aspects must be harmonised to create a pleasant, reliable and friendly 
environment that the customer enjoys.  
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6. Strategy proposal and evaluation 
In this chapter the present strategy of company ‘F’ is evaluated and the proposals for 
launching the product ‘A’ are stated so that the launch is as successful as possible. After, the 
prognosis of the market and market share is estimated followed by the economic evaluation. 
a. Present strategy evaluation 
 The company ‘F’ is a successful company and is an important player on the market of drugs. 
Nevertheless the market of inhalation anaesthetics is for the company not the most 
successful market. The market share has been even diminishing. The strategy generally is a 
successful strategy. The problem of inhalation anaesthetics is that the company has taken 
this area as defocused so far. Now it seeks to increase its sales in all areas including this. That 
is the reason for launching a new product.  
The strong positive factors of the strategy are: 
- High quality and innovative products 
- High quality supportive services 
- Informative and well-arranged web pages 
- Tight relations with distributors and wholesalers 
- Large marketing and sales team 
- Support of the mother company that sets the general strategy framework 
- Effective system of sales and marketing support 
- Precisely elaborated buying process 
- Focus on relevant groups (doctors, GPO contractors, tender authority, pharmacists) 
These factors are a proof of a promising strategy that company ‘F’ successfully applies. All of 
the products that are offered are of a very high quality and are in many cases unique. Also 
the quality of services accompanying the products is very high. To these the professional 
consulting, fast and in time deliveries or technical equipment can be mentioned. These all 
contribute to the better healthcare in general.  
78 
 
The deliveries are partly handled by the reliable wholesalers and distributors and the 
availability for final customers is secured via pharmacies. The sales are generated by the 
marketing and sales teams focused mainly on the relevant groups of customers and decision 
makers. The Czech and Slovak affiliates are supported by the mother company that gives 
them the general strategy framework but affiliates can adapt it for the local markets. So they 
are given relative freedom on what they should do.  
The sales are also supported by a set of tools such as direct mailing, telemarketing, 
prospects, point of sales (POS) visits, presents, free samples, support of doctors at 
congresses, organising of symposia and others. Very important are the elaborated turning 
points during the buying process so that it is easier to see on what steps the company should 
concentrate. This makes the activities most effective. 
b. Proposed strategy for launch of product ‘A’ 
In this chapter the strategy for the launch of the product ‘A’ is designed. It would be based 
on the previous analysis and it should be in accordance with the current strategy.  
i. Product 
Firstly the message concerning the product ‘A’ that should be transferred to the customers 
and decision makers is proposed. The main message should deliver that the product ‘A’ is an 
‘effective and safe inhalation anaesthetic for general anaesthesia sold at affordable price, 
delivered by the original inventor of this active substance and supported by high quality 
service’. It also should be emphasised that the generic product ‘A’ is AN rated and has the 
same efficacy as the original drug. Other important message should include that new 
modern vaporizers will be provided and installed for free followed by free after sale service 
and maintenance as well.  
Then the advantages of the new modern anaesthetics should be communicated. The 
customers should be aware that it allows fast early recovery and rapid return of cognitive 
function. It has been shown to decrease the post operation nausea and vomiting and it 
allows performing inhalation induction. Another alluring fact that should be mentioned is 
the possibility of sale of all three types of inhalation anaesthetics that are available on the 
market. 
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ii. Price 
The height of the manufacturer’s price is now set to 4 180 CZK which is in accordance with 
the intention to launch the product at a price 10 % lower than the competitive original drug. 
It is proposed to reduce the price by 10 % every year as the competitor is expected to lower 
the price too.  
This lower price should be competitive also at the tender bidding. The price lowering is 
considered also in the next chapter that evaluates the launch of the product ‘A’ from the 
economic point of view. 
Crucial will be the arrangement of the maximum price at the level of the manufacture price. 
The representatives of a company should be able to achieve this goal. The reimbursement 
will be a bit more difficult quest as the government would try to set it as low as possible. The 
interest of the company would be to set the reimbursement as high as possible. 
iii. Place 
Here the approach should be different according to the decision making process. If the most 
influence is on the anaesthesiologists the activity should be focused on them and also on the 
anaesthesia nurses. On the other hand when the management of medical facilities is the 
main decision maker on drug purchase this management has to be approached. In the case 
of major influence of medical facilities’ pharmacies the pharmacists should be the target 
group on which the marketing and sales activities should be pointed. Finally when there is a 
tender the tender committee or tender authorities should be in the viewpoint. A very special 
group and also one of the most important is the group of so called key opinion leaders (KOL). 
These should be definitely approached but differently. 
In most of the cases the drug should be distributed by distributors or wholesalers. Only in 
the case of tenders where the order would be of a larger amount the direct selling is the 
right choice. 
The most desired target is then the big hospitals with over 1 000 beds as there is the highest 
number of operations under general anaesthesia and the highest number of vaporisers 
placed. There also work the most anaesthesiologists. The decision making process varies 
from hospital to hospital so it is needed to check this process in every facility the company 
would like to deal with. The second most desired segment is the hospitals with less than 1 
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000 beds and other larger health centres. There is also the possibility of secondary focus on 
private health centres such as plastic surgeries where there are many operations under 
general anaesthesia. The data are though not publicly available.  
It is advised to concentrate specifically mainly on the tenders. There is a higher chance to 
succeed as usually the main criterion is the price. It is because the government wants to 
reduce the expenditures on health, especially drugs. 
iv. Promotion 
The main task of promotion is to transfer the message stated in previous part of this paper 
and to generate sales. It should be focused on the targeted segments stated above.  
Firstly the company should organise so called Launch symposium where the important KOLs 
should take part in. In this symposium the launch of the product should be solemnly 
declared. The KOLs should present the anaesthetic in a positive way and there should also be 
representatives of scientific journals related to the anaesthesia topic so that it is then 
published. It is very common and recommended to invite also at least one KOL from abroad. 
The content of the presentation should include the main message with other specifications 
and advantages of the product ‘A’. This should create a very promising initial awareness of 
the product because KOLs have a very strong influence on the professional public that could 
influence the purchase behaviour. 
At the same time the sales representatives should be going for visits at POS directly. They 
should inform the priority segments about the efficacy, prices and conditions of sales. They 
should also mention the granting of vaporizers. The vaporizers represent the biggest barrier 
as there are already vaporizers placed. It is important to deliver that the granted vaporizers 
are newer and better. The free samples could not be given as the product ‘A’ needs the 
vaporizers first that are too costly to provide as a free sample. Further, the propagation 
materials are definitely needed. 
Very beneficial is to organise so called ‘round table’ events where doctors should participate. 
In these events the doctors are informed about the benefits of the drug and they are given 
free refreshments. There is one medical doctor, called advocate, that has the knowledge of 
the product and the problematic and he gives a speech and answers the questions of others. 
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He gets paid for this event. There is also the representative of the company that coordinates 
the whole event. It is advised to invite mainly the more experienced doctors who have 
higher degree of influence so that the impact of these events is higher. 
It is then essential to organise other events during the next years continuously and to 
support doctors at congresses dedicated to the field of anaesthesia. It is also worth to partly 
finance the grants in the field of anaesthesia. The author proposes also to publish new 
scientific articles in journals. The articles should be about the generic product ‘A’ stating that 
it is comparable to the original drug and that it is safe, of a high quality which is 
unobjectionable. This is proposed because it is expected that the competitor will try to 
decrease the credibility of the generic drug in order to keep its market share. It is also 
helpful to found scientific forums and blogs about anaesthesia where the company should 
actively contribute and employ also the KOLs to participate and contribute too. The 
company should also join also already existing forums. 
The direct mailing is also recommended and mainly after the launch to already existing 
customers to keep them. The form of telemarketing is also still very effective tool for this 
product.  
For the support of sales it is recommended to offer also special deals. These could include 
the possibility of 10 % discount when the order is of more than 100 bottles a year. Another 
possible discount of 10 % can be assigned of the customer buys a full package of all three 
different types of anaesthesia. These could be very helpful tools for increasing the total sales 
and still achieve increasing profit. Other advised activity would include a special offer to 
returning customers in a form of 10 % discount again. This would help to keep the sales that 
have already been won. The attention should then be paid to the height of the price after 
first years as the price could possibly decrease below the costs which would lead to a loss.  
The costs for the propagation activities are estimated in the following part.  
v. People 
To reach the needed amount of customers and to be able to handle a successful launch it is 
needed to employ or outsource the needed staff. It is estimated that for the number of 
customers in the Czech Republic one Key account manager (KAM) and two product 
82 
 
managers will be needed. In the case of Slovakia one KAM for part –time and one full time 
PM are needed. The KAM are available via outsourcing for 100 000 CZK per month and the 
PM for 80 000 CZK per month8. The key account manager is expected to be sufficient only 
one for both markets after the first year of sales. The key account managers and product 
managers will be responsible for the POS visits. 
There is also an existing sales and marketing team available. The KAMs and PMs will be 
responsible for these teams too. The teams dispose of relatively high level interpersonal and 
communicative skills but do not possess the knowledge of the product. It is then advised to 
undergo special trainings for this staff. 
The training should consist of both the product training and anaesthesia grounding. The goal 
would be to shift from generalists to specialists in order to be capable of effective 
competition against the sales force of Competitor ‘B’. The content should also comprise of 
the knowledge of other anaesthetic agents that will be offered in the previously mentioned 
package. These trainings should also develop the skills of creating the counter arguments to 
Competitor ‘B’’s statements. The result of this should be mainly the arguments but also 
materials and other tools. It would be also helpful to intensify the commercial skills as well in 
order to improve the sales effectiveness even more.   
This all should be trained internally in the company but it should also be supported by the 
external trainings. This would involve establishing regional simulation centres and web based 
interactive training. This would increase the awareness of the training and accelerate the 
adoption of skills. It is recommended also to introduce peer to peer training including 
workshops and DVD’s training.  
Other very important people should be the Medical department team. This team of people 
would be responsible for the scientific part. They should possess the knowledge of the 
scientific background. Their job would involve the continuous monitoring of the scientific 
articles, generally the publications and they should know the trend and what is new.  
                                                      
8
 Internal resources 
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vi. Process 
  The process is corresponding with the process described in the previous analysis. In this 
chapter the individual steps and actions are stated to fit for the product ‘A’.  
In the phase of origination the customers have to be informed that the product ‘A’ is 
available in a generic form from the company ‘F’ and the qualification to be admitted for the 
tender should be secured. 
Then during the evaluation/diagnostic and treatment choice steps, if there is a tender or 
GPO contract and at the same time the sole award is in consideration, take this as the first 
priority and win the sole award whenever possible. This ensures the sale of also other types 
of anaesthetics. When it is the dual or multi award, Competitor ‘B’ is more likely to win as 
they have a bigger sales footprint in the field.  
The Brand choice/dosage phase offers the possibility to differentiate company ‘F’ by 
focusing on the world leadership in anaesthesia, unique product features and state-of-art 
vaporisers and thus persuade uncommitted customers to choose company ‘F’. 
The fulfilment step needs to ensure that the representatives develop a sustainable 
relationship with the customers to maximise contract compliance. The improved vaporisers 
coverage and utilisation should take place in order to maximise the account productivity. 
The last phase of persistence the most important activity is to proactively manage the 
tenders to ensure the desired sustainable growth. 
vii. Physical Evidence 
This area does not require any special or significant changes for the launch of product ‘A’ as 
the physical evidence is already in place. This includes the package of product, state-of-art 
vaporisers, templates, sales force and others. 
c. Prognosis and Economic evaluation 
In this part the prognosis of the market of inhalation anaesthetics and also the market share 
of the company ‘F’ is elaborated. It is than followed by the NPV model, ROI indicator and 
breakeven point. 
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i. Prognosis   
The prognosis has been elaborated on the basis of the historical sales of units from years 
2005 to 2010. The prognosis has been also conducted for the other anaesthetic agents: 
Desflurane and Isoflurane. The trend was estimated by the MS Excel function LINTREND. The 
market of Slovakia was after consulting with the head of business unit estimated on the 
basis of data from the Czech market due to insufficient data. The market of Czech Republic 
embodies similar development and similar market shares of individual companies as the 
Slovakia market.  
There have also been assigned specific parameters to individual anaesthetics to adapt the 
trend so that it can indicate the real development as much as possible. After the consulting 
the parameters with the management the parameter for product ‘A’ market has been stated 
1.05 as there will be more propagation of this substance from the company ‘F’ which would 
also implicate the promotion from competitor Competitor ‘B’. For the market of Desflurane 
the parameter was estimated at 1.03 as it would be promoted only by company ‘F’. The 
Isoflurane market on the other hand received a parameter of 0.97 as this drug will be less 
promoted because it is an older anaesthetic.  
The prognosis of the value of the market stems from the prognosis of the volume terms. The 
average price has been prognosticated as well with the help of LINTREND function. The 
market’s value terms have then been obtained by multiplying the volume terms by the 
prognosticated prices. In the case of Sevofulrane, as there are two competitors, the result 
was obtained by splitting the volume terms according to the prognosticated market shares 
of the two competitors. The market share has been prognosticated on the basis of the 
activities recommended in previous chapter and available market shares of company ‘F’ 
entering the market in the USA. The whole prognosis is worked out for next five years. The 
results of the prognosis are seen in tables below. 
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Table 22: Czech market prognosis *
* The market is prognosticated using the Excel function LINTREND (based on historical data) with associated 
parameters and the prognosis for company ‘F’ is based on the data from the previous penetration of the 
market of the United States of America.  
References: SUKL (www.sukl.cz); Internal materials 
Table 23: Slovakian market prognosis: value (CZK)* 
* Estimated according to the data of the Czech market (exchange rate CZK/EUR=24.19) 
Table 24: Slovakian market: Company ´F´* 
* Estimated according to the data of the Czech market (Exchange rate CZK/EUR=24.19) 
ii. NPV model 
After the prognosis of the market the NPV model is designed and it should evaluate the 
overall launch of the product ‘A’. Before going to the specific calculations of the model it is 
needed to define the assumptions of this model.  
Firstly it is assumed that the price of product ‘A’ will decrease by 10 % every year as 
explained previously. Another assumption is the price of the vaporisers that have been 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
CZK (SUKL)
Halothan 5,192,729          4,949,712         2,677,853         1,981,268         344,256             -                       -                        -                        -                        -                        -                        -                        
av. Price 806                      791                     794                     826                     834                     -                       -                        -                        -                        -                        -                        -                        
Isofluran 41,611,594        37,371,681       40,366,714       39,507,823       40,743,258       44,000,595       29,934,735        30,303,465        30,602,808        30,832,764        30,993,332        31,084,513        
av. Price 1,237                  1,241                  1,075                  1,115                  1,154                  1,047                  1,018                  989                      959                      930                      901                      
Desfluran 750,688              579,361             1,160,672         1,288,537         1,522,284         965,372             822,051              836,520              851,242              866,224              881,470              896,984              
av. Price 2,694                  2,105                  2,085                  2,001                  1,921                  1,844                  1,771                  1,700                  
Sevofluran 69,430,108        77,406,630       93,117,095       96,357,182       101,319,726     102,449,319     83,107,676        80,359,183        77,328,888        74,119,233        70,766,948        67,338,243        
Sevoflurane ´F´ 2,006                  2,732                  3,445                  4,781                  5,687                  6,354                  
celkem 116,985,118     120,307,384     137,322,333     139,134,810     143,929,523     147,415,285     113,864,462     111,499,168     108,782,938     105,818,221     102,641,750     99,319,740        
Sevoflurane MS 10% 13% 15% 20% 22% 23%
Number of units
Halothan 6,443                  6,259                  3,373                  2,400                  413                     -                       -                        -                        -                        -                        -                        -                        
Isofluran 23,216                22,810               23,310               26,219               26,862               28,752               28,585                29,770                30,955                32,139                33,324                34,508                
Desfluran 196                      138                     134                     66                        486                     372                     394                      418                      443                      470                      498                      528                      
Sevofluran 9,923                  11,788               14,859               15,003               16,101               17,212               20,055                21,541                23,027                24,513                25,999                27,485                
total 39,778                40,995               41,676               43,688               43,862               46,336               49,035                51,729                54,425                57,122                59,821                62,521                
Sevoflurane 32,427,818             35,132,306             37,427,753             38,628,828             40,978,442    39,008,548      36,952,431    34,864,377    32,764,556    30,685,624    
Desflurane 572,762                   651,226                   743,407                   482,733                   403,825          404,875            405,927          406,983          408,041          409,102          
Isoflurane 14,274,717             14,242,985             14,626,922             16,587,655             14,720,006    14,680,525      14,605,333    14,496,001    14,354,052    14,180,970    
total 47,275,297             50,026,516             52,798,082             55,699,215             55,699,215    55,699,215      55,699,215    55,699,215    55,699,215    55,699,215    
Sevoflurane total (CZK) 32,427,818             35,132,306             37,427,753             38,628,828             40,978,442    39,008,548      36,952,431    34,864,377    32,764,556    30,685,624    
share of sales SK/CZ 49.35% 50.54% 48.83% 50.00% 49.31% 48.54% 47.79% 47.04% 46.30% 45.57%
units 7,333                        7,583                        7,863                        8,607                        9,889               10,457              11,004             11,530             12,037             12,525             
units ´ F´ 989                   1,326                1,646               2,249               2,633               2,895               
number of vaporizers 39 11 9 18 9 5
86 
 
offered for 33,990 CZK9. The lifetime of the vaporisers is set to 10 years which is important 
for calculating the depreciation. The planned vaporiser’s depreciation is in the Table 25: 
Vaporizers depreciation. The number of vaporisers has been also prognosticated according 
to the prognosticated market share of company ‘F’.  The number of vaporisers for substance 
‘A’ is estimated to be 800 in the Czech Republic and 40010. The specific numbers of the 
vaporizers are stated in the Table 26: Table of assumptions. Then the wages of the KAMs and 
PMs are taken into consideration as mentioned above. The increase of the wages is 
estimated at 5 % annually. The corporate tax has been set at 19 % for all of the planned 
years. The most important is the estimation of costs of goods sold. These include the 
rewards for sales and marketing team and also all the activities proposed above. After the 
consulting with the management the costs are estimated to be 50 % of sales that decreases 
to 20 % in the last year because the activities will be less intensive. The continuous decrease 
is stated in Table 26: Table of assumptions and Table 27:  Table of Assumptions (Slovakia). 
Finally the discount rate has been calculated to be 10 %.  
Table 25: Vaporizers depreciation* 
 
*Based on the expected life time of 10 years.  
                                                      
9
 The vaporisers at this price have been offered by the manufacturer of vaporisers Dräger Medical Ltd. (Internal 
sources) 
10
 Internal sources 
Vap depreciation CZ (CZK) 2010 2011 2012 2013 2014 2015 2016
Vaporizer cost 2,719,200  729,387     619,788     1,234,816  645,212     337,764     
depreciation 2011 271,920     72,939        61,979        123,482     64,521        33,776        
depreciation 2012 271,920     72,939        61,979        123,482     64,521        
depreciation 2013 271,920     72,939        61,979        123,482     
depreciation 2014 271,920     72,939        61,979        
depreciation 2015 271,920     72,939        
depreciation 2016 271,920     
total -       271,920     344,859     406,837     530,319     594,840     628,617     
Vap depreciation SK (CZK) 2010 2011 2012 2013 2014 2015 2016
Vaporizer cost 1,341,857  368,631     302,673     617,468     318,139     163,960     
depreciation 2011 134,186     36,863        30,267        61,747        31,814        16,396        
depreciation 2012 134,186     36,863        30,267        61,747        31,814        
depreciation 2013 134,186     36,863        30,267        61,747        
depreciation 2014 134,186     36,863        30,267        
depreciation 2015 134,186     36,863        
depreciation 2016 134,186     
total -       134,186     171,049     201,316     263,063     294,877     311,273     
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Reference: Author´s calculations 
Table 26: Table of assumptions (CZ) 
Reference: Internal sources 
Table 27:  Table of Assumptions (Slovakia) 
Reference: Internal materials 
The NPV model itself then calculates the net present value of the planned launch. The 
revenues are taken as estimated number of units sold multiplied by the price of a unit. The 
calculated number represents the gross sales. Then the costs of goods, calculated as 
percentage of sales, are subtracted. Also the labour costs are subtracted. The result is the 
gross profit. To see the development of ration of costs to sales the gross profit margin is 
calculated.  
From the gross profit the vaporisers’ depreciation is subtracted resulting in earnings before 
interest and tax (EBIT). After, the tax is subtracted and the outcome is net profit. As the 
interest is not assumed it is not subtracted. To get free cash flow (FCF) we have to add the 
costs that are not actually paid and add expenses that are not costs. These include the 
vaporisers’ depreciation which is subtracted and the expenses to buy the vaporisers are 
Continuous price decrease 10%
Vaporizer price 33990
Number of Vaporizers 80 21 18 36 19 10
Vaporizer cost 2719200 729387 619788 1234816 645212 337764
Cost of goods 50% 40% 30% 25% 23% 20%
Product Manager/month 80000 84000 88200 92610 97241 102103
Key account manager/month 100000 50000 52500 55125 57881 60775
Unit cost (USD) 53.04
Exchange rate CZK/USD 19.3.2011 17.26
Unit cost (CZK) 916
Cost annual increase 2%
Labour cost annual increase 5%
Discount rate 10%
Corporate tax 19%
Vaporizer life (years) 10
Continuous price decrease 10%
Vaporizer price 33990
Number of Vaporizers 39 11 9 18 9 5
Vaporizer cost 1341857 368631 302673 617468 318139 163960
Cost of goods 50% 40% 30% 25% 23% 20%
Product Manager/month 80000 40000 42000 44100 46305 48620
Key account manager/month 75000 0 0 0 0 0
Unit cost (USD) 53.04
Exchange rate CZK/USD 19.3.2011 17.26
Unit cost (CZK) 916
Cost annual increase 2%
Labour cost annual increase 5%
Discount rate 10%
Corporate tax 19%
Vaporizer life (years) 10
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added. Then the discount factor is calculated and the FCF is then multiplied by the discount 
factor resulting in discounted cash flow (DCF). Then the sum of DCF of all years represents 
the first part of the NPV. There is also estimated that the plan of sales has the second phase 
whose NPV is calculated as the FCF of the last year of the first phase divided by the discount 
rate. This is called the Terminal value. Then the sum of the NPV of first phase and of the 
Terminal value is the total NPV. The Table 28: NPV model showing the calculation of NPV is 
below.  
Table 28: NPV model* 
 
 
* The price is estimated to be 4180 CZK for the first with decrease of 10 % every year. The number of units sold 
Czech Republic 2010 2011 2012 2013 2014 2015 2016
Std Units -              2,006                   2,732                   3,445                   4,781                   5,687                   6,354                   
Gross ASP -              4,180                   3,762                   3,386                   3,047                   2,742                   2,468                   
Gross Sales 8,383,095          10,277,467        11,664,778        14,567,713        15,597,483        15,682,644        
Cost of goods 4,191,547          4,110,987          3,499,433          3,641,928          3,587,421          3,136,529          
Labor Cost 2,160,000          1,608,000          1,688,400          1,772,820          1,861,461          1,954,534          
Mgmt Gross Profit (Net) 2,031,547          4,558,480          6,476,945          9,152,965          10,148,601        10,591,581        
MGP in % of Sales (Net) 24% 44% 56% 63% 65% 68%
Vap Depreciation 271,920              344,859              406,837              530,319              594,840              628,617              
EBIT 1,759,627          4,213,622          6,070,107          8,622,646          9,553,760          9,962,964          
Tax 334,329              800,588              1,153,320          1,638,303          1,815,214          1,892,963          
Net profit 1,425,298          3,413,034          4,916,787          6,984,343          7,738,546          8,070,001          
Vap Cost 2,719,200          729,387              619,788              1,234,816          645,212              337,764              
FCF 1,021,982 -         3,028,506          4,703,836          6,279,846          7,688,174          8,360,853          
Discount factor 1.0000 0.9091 0.8264 0.7513 0.6830 0.6209
DCF 1,021,982 -         2,753,187          3,887,468          4,718,141          5,251,126          5,191,432          
Terminal value 83,608,535        
NPV 20,779,373        
NPV including TV 104,387,907      
Slovakia 2010 2011 2012 2013 2014 2015 2016
Std Units -              989                      1,326                   1,646                   2,249                   2,633                   2,895                   
Gross ASP -              4,180                   3,762                   3,386                   3,047                   2,742                   2,468                   
Gross Sales 4,133,507          4,988,964          5,574,138          6,852,395          7,221,515          7,146,484          
Cost of goods 2,066,753          1,995,586          1,672,241          1,713,099          1,660,949          1,429,297          
Labor Cost 1,860,000          480,000              504,000              529,200              555,660              583,443              
Mgmt Gross Profit (Net) 206,753              2,513,378          3,397,897          4,610,096          5,004,907          5,133,744          
MGP in % of Sales (Net) 5% 50% 61% 67% 69% 72%
Vap Depreciation 134,186              171,049              201,316              263,063              294,877              311,273              
EBIT 72,568                2,342,330          3,196,581          4,347,033          4,710,030          4,822,472          
Tax 13,788                445,043              607,350              825,936              894,906              916,270              
Net profit 58,780                1,897,287          2,589,230          3,521,097          3,815,124          3,906,202          
Vap Cost 1,341,857          368,631              302,673              617,468              318,139              163,960              
FCF 1,148,892 -         1,699,704          2,487,873          3,166,692          3,791,862          4,053,515          
Discount factor 1.0000 0.9091 0.8264 0.7513 0.6830 0.6209
DCF 1,148,892 -         1,545,186          2,056,093          2,379,182          2,589,893          2,516,914          
Terminal value 40,535,149        
NPV 9,938,377          
NPV including TV 50,473,525        
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is taken from the previous market prognosis. Costs are calculated according to the prognosticated strategic 
activities. 
References: Author´s calculation 
iii. Return on Investment 
To evaluate the effectives of the investments into this project the ROI is used. It is calculated 
as the sum of gross sales and expenses that are not costs and then costs that are not 
expenses are subtracted. This number is then divided by the expenses. The ROI is calculated 
for every year. For all years it resulted in number that is bigger than one which is acceptable. 
It is rapidly increasing and in the last year of the plan reaches 284 % in the case of the Czech 
Republic and 322 % in the case of Slovakia. The ROI is stated in the Table 29: ROI.  
Table 29: ROI 
 
Reference: Author´s calculations from the previous prognosis and NPV model. 
iv. Breakeven point 
The breakeven point is used to see how many units at least have to be sold to make up for 
the costs. This means that at this number of units the profit is zero. The breakeven point is 
calculated for the overall costs, for the cost of vaporizers and also for the cost of the labour 
force. The basic formula is the ratio of fixed costs and the residual of price per unit and 
variable cost per unit.  
The breakeven point for the overall costs was calculated to be around 1000 units per year in 
the Czech Republic and around 400 in Slovakia depending on each year. It is clear that there 
is a quite large safety margin meaning the difference of estimated sales and the breakeven 
point.  
When we look at the breakeven point for covering the costs of vaporisers we see that the 
monthly sales of units are very low, not even exceeding 0.2 and 0.13. The vaporisers can 
thus be provided to customers even with low consumption of the anaesthetic but they have 
to realise the sales for 10 years (the same time as the vaporiser lifetime). 
ROI (CZ) 119% 165% 205% 230% 257% 284%
ROI (SK) 101% 182% 229% 252% 286% 322%
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Lastly the minimal number units sold to cover the labour costs varies from 59 to 86 
respectively 18 to 74 units sold per month, which is significantly more than the vaporisers 
coverage. On the other hand the safety margin is still very high. 
The individual calculations of breakeven points are shown in the tables below. 
Table 30: Breakeven points (CZ) 
Reference: Author´s calculation from the previous prognosis and NPV model. 
Table 31: Breakeven points (SK) 
Reference: Author´s calculation from the previous prognosis and NPV model. 
v. Sensitivity analysis 
Finally the sensitivity analysis was elaborated. It is used to see how the results are changed 
when the input variables change. It can be applied to all of the input variables. In the case of 
product ‘A’ the dependence of the total NPV on price depreciation percentage, vaporiser’s 
price, discount rate, vaporiser’s lifetime and percentage of costs of goods was calculated.  
It has been proved that the total NPV is mostly dependent on the price depreciation 
percentage and the height of the discount rate. These influence the NPV almost by 100 %. 
On the other hand the NPV is least dependent on the vaporiser price and lifetime that 
change the result only slightly. The specific values for different sensitivity analyses are 
recorded in the appendix 7. 
vi. Strategy timeline 
Finally the timeline of the specific strategic activities and needed steps including the total 
costs and total sales in every year is presented. It can be found in Figure 5: Strategy timeline. 
BEP total 1,164                   865                      884                      1,008                   1,163                   1,308                   
BEP (Vap cost,monthly) 0.136                   0.125                   0.120                   0.124                   0.134                   0.143                   
BEP (labor costs,monthly) 86                         59                         59                         65                         73                         82                         
BEP total 954                      288                      298                      347                      403                      453                      
BEP (Vap cost,monthly) 0.136                   0.125                   0.120                   0.124                   0.134                   0.143                   
BEP (labor costs,monthly) 74                         18                         18                         19                         22                         25                         
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Figure 5: Strategy timeline
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7. Conclusion 
In this diploma thesis the launching strategy for the Product ‘A’ offered by Company ‘F’ is 
proposed followed by the economic evaluation of the incremental sales generated by the 
Product ‘A’. The launch strategy was designed specifically for the Czech and Slovak market.   
The markets of the Czech Republic and Slovakia were analysed on the basis of the theoretical 
models introduced in the theoretical part. The analyses evidenced that the markets show 
similar characteristics and developments and so the strategy is designed for both markets 
without significant differences. The publicly available data of Slovakian market are 
insufficient so the author estimated the needed data with the help of the data of the Czech 
market.  
Both of the markets are suitable for launching of a new generic drug. The growth of the 
pharmaceutical sales has been continuously increasing. The sales of generics have been 
growing more rapidly which favours the launch even more. The pharmaceutical market is 
large both in value and volume terms. What more the countries are highly ranked according 
to the analyses elaborated by reputable authorities.   
It has been argued that there are two main competitors on the market for Company ‘F’ out 
of which one is direct competitor. This direct competitor has a major influence on the 
market as it possesses the majority of sales on the market both in values and volume. 
Company ‘F’ is though offering slightly different drug as it is a generic one to the 
competitor´s original drug. The other competitor is thus an indirect one offering similar 
drugs in the field of inhalation anaesthetic agents. 
As Company ‘F’ is already present on the market it has a significant experience which is 
advised to utilise during the launch and further sales of the new Product ‘A’. There are also 
plenty of new strategic points proposed.  
The strategy has been suggested with the help of the 7 P´s marketing model discussed in this 
paper. The major importance is put on the sales and marketing teams that will be conducted 
by the key account managers and project managers. It is advised to train the sales and 
marketing teams not only in selling skills but also to increase the level of knowledge of all the 
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products offered by Company ‘F’ in the field of inhalation anaesthetics and also of the 
scientific background. The second type of training is considered to be even more important.  
Secondly the target groups are introduced. The major interest should be put on the target 
groups such as medical doctors, nurses, management of the medical facilities and also the 
tender committees depending on the type of decision making process. The most important 
and profitable target segments should include big hospitals that are mostly faculty hospitals. 
In these the contracts are of the biggest volume and thus of the highest possible sales. These 
contracts are also the most profitable in relation to the needed new vaporizers offered for 
free by Company ‘F’. 
Other very important strategic area is the form of promotion of the Product ‘A’. It is 
proposed to start the launch with the Launch Symposium on which also the foreign and 
reputable doctors should be present. Other important activities include the Round Table 
Events conducted by the advocate who should be represented by a reputable domestic 
doctor who is at the same time a key opinion leader in this area. Others should include the 
visits by representatives directly at the point of sales meaning the hospitals and medical 
facilities itself. 
Crucial is also to offer lower price than the main competitor Abbott as Product ‘A’ is only the 
generic drug. This is considered to be the decisive motivation that would turn the potential 
customers to Company ‘F’’s side. Other important motivating factor would be the provision 
of new state of art vaporizers and the possibility of buying all three types of anaesthetic 
agents used during surgeries.  
Taking into consideration the proposed strategy the NPV model has been developed. The 
incremental sales and costs are estimated. There has been set a series of assumptions 
including discount rate, labour costs, vaporiser life, corporate tax, costs annual increase, 
labour costs annual increase and continuous price decrease. Given these assumptions and 
the estimation of total incremental sales reaching 112 090 183 CZK and costs reaching             
32 705 770 CZK the NPV was calculated to be 104.4 million CZK for the Czech Republic and 
50.5 million CZK for Slovakia. The total NPV has thus been resulted to be 154.9 million CZK. 
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To evaluate this NPV economically the Return on investment analysis has been calculated 
followed by the Breakeven point analysis and Sensitivity analysis. All of these analyses 
reached favourable positive numbers which supports the vision of successful launching of 
Product ‘A’. The sensitivity analysis showed that the value of NPV is mostly dependent on 
the price decline and the discount rate. The biggest risk is thus seen mainly in the danger of 
decreasing the price of Product ‘A’. Nevertheless the breakeven point analysis proved that 
the safety margin is high which gives Company ‘F’ a strong shelter. The launch of Product ‘A’ 
should then be a success. 
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Reference: Pozor klíště 
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Appendix  7) Sensitivity Analysis
Price depreciation (%)NPV
0 33,512,621        
5 27,005,626        
10 21,395,397        
15 16,578,365        
20 12,459,696        
25 8,952,884          
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NPV + TV
190,793,693        
145,354,319        
108,199,657        
78,120,931           
54,034,265           
34,973,831           
-myslete-taky-na-
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Reference: Author´s calculation from the NPV model. 
 
Vap price (CZK) NPV NPV + TV
20000 23,482,362        111,185,239        
30000 21,990,607        109,051,156        
40000 20,498,852        106,917,073        
50000 19,007,096        104,782,990        
Discount rate NPV NPV + TV
5 25,161,180        198,769,701        
10 21,395,397        108,199,657        
15 18,374,231        76,243,738           
Vap life NPV NPV + TV
5 21,733,410        108,698,746        
10 21,395,397        108,199,657        
15 21,261,339        107,667,475        
Cost of goods (%) NPV NPV + TV
20 26,429,089        113,233,350        
30 21,674,189        95,775,508           
40 16,919,288        78,317,666           
50 12,164,388        60,859,824           
60 7,409,487          43,401,982           
